11110769	183	Frustaci A	Myocardial cell death in human diabetes.	Circulation research	2000	164
11937178	183	Dahlöf B	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.	Lancet	2002	438
15149345	183	de Zeeuw D	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.	Kidney international	2004	141
15302780	183	de Zeeuw D	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.	Circulation	2004	99
15592481	183	Heilbronn L	Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus.	International journal of obesity and related metabolic disorders 	2004	87
15919782	183	Wolf G	From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy.	Diabetes	2005	124
17409317	183	Eijkelkamp WB	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.	Journal of the American Society of Nephrology 	2007	57
18607402	183	Dronavalli S	The pathogenesis of diabetic nephropathy.	Nature clinical practice. Endocrinology and metabolism	2008	93
19145003	183	Parving HH	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.	Nephrology, dialysis, transplantation 	2009	51
20819950	183	de Cavanagh EM	Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?	Cardiovascular research	2011	35
21670228	183	Goossens GH	Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation.	Circulation	2011	53
24776703	183	Jiang F	Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.	Nature reviews. Cardiology	2014	24
25767285	183	Hall JE	Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.	Circulation research	2015	52
26116691	183	Lin X	Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.	Journal of the American Heart Association	2015	24
16567827	197	Stefan N	Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.	Diabetes care	2006	88
18612115	197	Ix JH	Fetuin-A and incident diabetes mellitus in older persons.	JAMA	2008	64
18633113	197	Stefan N	Plasma fetuin-A levels and the risk of type 2 diabetes.	Diabetes	2008	73
19029462	197	Weikert C	Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke.	Circulation	2008	58
20664518	197	Sage AP	Regulatory mechanisms in vascular calcification.	Nature reviews. Cardiology	2010	87
22426755	197	Montonen J	Consumption of red meat and whole-grain bread in relation to biomarkers of obesity, inflammation, glucose metabolism and oxidative stress.	European journal of nutrition	2013	26
23337953	197	Stefan N	The role of hepatokines in metabolism.	Nature reviews. Endocrinology	2013	33
11696579	207	Du XL	Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.	The Journal of clinical investigation	2001	165
14693694	207	Adams JM 2nd	Ceramide content is increased in skeletal muscle from obese insulin-resistant humans.	Diabetes	2004	140
15023346	207	Hanada M	Structure, regulation and function of PKB/AKT--a major therapeutic target.	Biochimica et biophysica acta	2004	157
15533996	207	Manning BD	Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.	The Journal of cell biology	2004	170
16123357	207	Tremblay F	Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability.	Diabetes	2005	93
16186396	207	Plomgaard P	Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation.	Diabetes	2005	91
17204661	207	Minamino T	Vascular cell senescence: contribution to atherosclerosis.	Circulation research	2007	104
17311546	207	Maiese K	Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus.	Current neurovascular research	2007	62
17452018	207	Dann SG	mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.	Trends in molecular medicine	2007	161
17627510	207	Maiese K	Mechanistic insights into diabetes mellitus and oxidative stress.	Current medicinal chemistry	2007	64
17647198	207	Chong ZZ	The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.	Histology and histopathology	2007	79
19026743	207	Zhao WQ	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.	Biochimica et biophysica acta	2009	56
19066370	207	Lippman SM	Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).	JAMA	2009	470
19800084	207	Zhang H	Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.	Metabolism	2010	49
20117946	207	Krycer JR	The Akt-SREBP nexus: cell signaling meets lipid metabolism.	Trends in endocrinology and metabolism	2010	49
20182580	207	Liao Y	Physiological regulation of Akt activity and stability.	American journal of translational research	2010	96
21385509	207	Brasnyó P	Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.	The British journal of nutrition	2011	104
21568903	207	Raimondi C	Targeting PDK1 in cancer.	Current medicinal chemistry	2011	39
23070488	207	Broussard JL	Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study.	Annals of internal medicine	2012	67
23255107	207	Würth R	Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.	Cell cycle	2013	52
23470275	207	O' Neill C	PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.	Experimental gerontology	2013	30
23493574	207	Chen YH	miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance.	Diabetes	2013	31
23852728	207	Betz C	Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology.	Proceedings of the National Academy of Sciences of the United States of America	2013	63
24373826	207	Mancuso C	Ferulic acid: pharmacological and toxicological aspects.	Food and chemical toxicology 	2014	20
24998913	207	Lee JV	Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.	Cell metabolism	2014	64
25399420	207	Gao Y	The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells.	Nucleic acids research	2014	34
25689954	207	Courtnay R	Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.	Molecular biology reports	2015	27
10335783	213	Schmidt MI	Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study.	Lancet	1999	153
11961019	213	Paniagua R	Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.	Journal of the American Society of Nephrology 	2002	91
15625072	213	Muntner P	Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.	Journal of the American Society of Nephrology 	2005	90
24025647	213	Hung SC	Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease.	Kidney international	2014	29
11535564	335	Sharrett AR	Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.	Circulation	2001	132
16330696	335	Steyn K	Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study.	Circulation	2005	79
16629855	335	Walldius G	The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.	Journal of internal medicine	2006	70
17227980	335	Joshi P	Risk factors for early myocardial infarction in South Asians compared with individuals in other countries.	JAMA	2007	154
20466975	335	Fryirs MA	Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.	Arteriosclerosis, thrombosis, and vascular biology	2010	42
20713683	335	Divoux A	Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss.	Diabetes	2010	82
22219194	335	Shao B	Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions.	The Journal of biological chemistry	2012	45
23965489	335	Boekholdt SM	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.	Circulation	2013	30
26025389	335	Saleheen D	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.	The lancet. Diabetes and endocrinology	2015	45
27431356	335	O'Donnell MJ	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.	Lancet	2016	28
8596596	338	Després JP	Hyperinsulinemia as an independent risk factor for ischemic heart disease.	The New England journal of medicine	1996	137
16463046	338	Adiels M	Overproduction of large VLDL particles is driven by increased liver fat content in man.	Diabetologia	2006	107
16476102	338	Barter PJ	Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.	Journal of internal medicine	2006	68
18458145	338	Fonseca VA	Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.	Diabetes care	2008	51
18832751	338	Shaw JA	Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.	Circulation research	2008	64
22893714	338	Benn M	Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.	The Journal of clinical endocrinology and metabolism	2012	52
24013058	338	Thomas GS	Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.	Journal of the American College of Cardiology	2013	30
24623100	338	Fenzl A	Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals.	Diabetologia	2014	37
25082583	338	Boekholdt SM	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.	Journal of the American College of Cardiology	2014	32
25555214	338	Fabbrini E	Metabolically normal obese people are protected from adverse effects following weight gain.	The Journal of clinical investigation	2015	30
25756439	338	Besseling J	Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.	JAMA	2015	24
12558712	348	Haan MN	Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors.	Journal of the American Geriatrics Society	2003	97
14568809	348	Lopez OL	Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.	Archives of neurology	2003	89
15911795	348	Enzinger C	Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.	Neurology	2005	71
16786033	348	Martins IJ	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease.	Molecular psychiatry	2006	78
17030648	348	Scarmeas N	Mediterranean diet, Alzheimer disease, and vascular mediation.	Archives of neurology	2006	74
17420320	348	Luchsinger JA	Relation of diabetes to mild cognitive impairment.	Archives of neurology	2007	128
18195144	348	Irie F	Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study.	Archives of neurology	2008	64
18663180	348	Cramer C	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.	Neurology	2008	56
18667359	348	Kalaria RN	Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.	The Lancet. Neurology	2008	149
19273753	348	Helzner EP	Contribution of vascular risk factors to the progression in Alzheimer disease.	Archives of neurology	2009	69
19362884	348	Knopman DS	Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study.	Alzheimer's and dementia 	2009	67
19918254	348	Fotuhi M	Changing perspectives regarding late-life dementia.	Nature reviews. Neurology	2009	77
20031276	348	Rasgon NL	Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.	Neurobiology of aging	2011	41
20032288	348	Roe CM	Cancer linked to Alzheimer disease but not vascular dementia.	Neurology	2010	47
20739645	348	Ahtiluoto S	Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study.	Neurology	2010	90
20739649	348	Matsuzaki T	Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study.	Neurology	2010	79
20837822	348	Baker LD	Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.	Archives of neurology	2011	125
21115952	348	Schrijvers EM	Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study.	Neurology	2010	63
21245181	348	Yaffe K	Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline.	JAMA	2011	54
22095980	348	Averill MM	S100A8 and S100A9 in cardiovascular biology and disease.	Arteriosclerosis, thrombosis, and vascular biology	2012	34
22232206	348	Head D	Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.	Archives of neurology	2012	56
22670023	348	Lal C	Neurocognitive impairment in obstructive sleep apnea.	Chest	2012	50
23601373	348	Bangen KJ	APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline.	Journal of stroke and cerebrovascular diseases 	2013	27
23670794	348	Martínez-Lapiscina EH	Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial.	Journal of neurology, neurosurgery, and psychiatry	2013	39
25633388	348	Marioni RE	DNA methylation age of blood predicts all-cause mortality in later life.	Genome biology	2015	114
25672924	348	Wang R	Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline.	Neurology	2015	18
26214150	348	Willette AA	Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease.	JAMA neurology	2015	23
26863354	348	Satizabal CL	Incidence of Dementia over Three Decades in the Framingham Heart Study.	The New England journal of medicine	2016	56
8140421	359	Deen PM	Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine.	Science	1994	131
24625825	359	Verkman AS	Aquaporins: important but elusive drug targets.	Nature reviews. Drug discovery	2014	54
22614056	551	Enhörning S	Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort.	International journal of obesity	2013	25
11118008	966	Hundal RS	Mechanism by which metformin reduces glucose production in type 2 diabetes.	Diabetes	2000	159
16253727	966	Gelber RP	Association between body mass index and CKD in apparently healthy men.	American journal of kidney diseases 	2005	73
17287462	966	Befroy DE	Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients.	Diabetes	2007	114
18295053	966	Zhang L	Prevalence and factors associated with CKD: a population study from Beijing.	American journal of kidney diseases 	2008	55
18337481	966	Weiner DE	Uric acid and incident kidney disease in the community.	Journal of the American Society of Nephrology 	2008	75
18678616	966	Phielix E	Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients.	Diabetes	2008	64
19358576	966	Tycko R	Evidence for novel beta-sheet structures in Iowa mutant beta-amyloid fibrils.	Biochemistry	2009	53
19394734	966	Shah SN	Serum bicarbonate levels and the progression of kidney disease: a cohort study.	American journal of kidney diseases 	2009	50
19567526	966	Nedeltcheva AV	Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance.	The Journal of clinical endocrinology and metabolism	2009	80
20138414	966	White SL	Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study.	American journal of kidney diseases 	2010	56
20172445	966	Stevens LA	Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP).	American journal of kidney diseases 	2010	56
20332400	966	Hemmelgarn BR	Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate.	JAMA	2010	51
20371664	966	Donga E	A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects.	The Journal of clinical endocrinology and metabolism	2010	73
20385436	966	Bellomo G	Association of uric acid with change in kidney function in healthy normotensive individuals.	American journal of kidney diseases 	2010	42
20441712	966	Black C	Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.	Health technology assessment	2010	43
20557989	966	Stevens LA	Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2.	American journal of kidney diseases 	2010	105
20884698	966	Di Angelantonio E	Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.	BMJ	2010	44
21098347	966	Roussel R	Metformin use and mortality among patients with diabetes and atherothrombosis.	Archives of internal medicine	2010	47
21403038	966	de Boer IH	Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.	Archives of internal medicine	2011	64
21656330	966	Lim EL	Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.	Diabetologia	2011	121
21693741	966	de Boer IH	Temporal trends in the prevalence of diabetic kidney disease in the United States.	JAMA	2011	163
22028277	966	Zoppini G	Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.	Diabetes care	2012	33
22206742	966	Jotwani V	Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.	American journal of kidney diseases 	2012	31
22770927	966	Roshanravan B	A prospective study of frailty in nephrology-referred patients with CKD.	American journal of kidney diseases 	2012	46
23111824	966	Hallan SI	Age and association of kidney measures with mortality and end-stage renal disease.	JAMA	2012	95
24182662	966	Yang W	Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.	American journal of kidney diseases 	2014	24
25552421	966	Udell JA	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.	Diabetes care	2015	19
25562264	966	Livingstone SJ	Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.	JAMA	2015	32
26337133	966	Grams ME	Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data.	American journal of kidney diseases 	2016	19
26867814	966	Obi Y	Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study.	American journal of kidney diseases 	2016	13
26906014	966	Billings FT 4th	High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.	JAMA	2016	21
17463246	1029	Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research.	Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.	Science	2007	1018
17463248	1029	Scott LJ	A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.	Science	2007	989
17478681	1029	McPherson R	A common allele on chromosome 9 associated with coronary heart disease.	Science	2007	479
17717515	1029	Sharpless NE	How stem cells age and why this makes us grow old.	Nature reviews. Molecular cell biology	2007	260
18469204	1029	Ng MC	Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians.	Diabetes	2008	118
18633108	1029	Wu Y	Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population.	Diabetes	2008	75
19002430	1029	Cho YM	Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population.	Diabetologia	2009	54
19862325	1029	Hu C	PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a Chinese population.	PloS one	2009	59
20386740	1029	Cunnington MS	Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression.	PLoS genetics	2010	100
20424228	1029	Chauhan G	Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians.	Diabetes	2010	44
21573907	1029	Parra EJ	Genome-wide association study of type 2 diabetes in a sample from Mexico City and a meta-analysis of a Mexican-American sample from Starr County, Texas.	Diabetologia	2011	44
22888763	1029	Jeck WR	Review: a meta-analysis of GWAS and age-associated diseases.	Aging cell	2012	37
23382687	1029	Pendergrass SA	Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network.	PLoS genetics	2013	47
23462794	1029	Dayeh TA	Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets.	Diabetologia	2013	47
24296717	1029	Dimas AS	Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity.	Diabetes	2014	63
26950362	1029	Helman A	p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion.	Nature medicine	2016	19
14559957	1071	Barzilai N	Unique lipoprotein phenotype and genotype associated with exceptional longevity.	JAMA	2003	157
15925013	1071	Ginsberg HN	Regulation of plasma triglycerides in insulin resistance and diabetes.	Archives of medical research	2005	78
20694148	1071	Zabaneh D	A genome-wide association study of the metabolic syndrome in Indian Asian men.	PloS one	2010	40
25541553	1071	Agha G	Adiposity is associated with DNA methylation profile in adipose tissue.	International journal of epidemiology	2015	15
25651499	1071	Benton MC	An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss.	Genome biology	2015	32
6367724	1351	Klein R	The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.	Archives of ophthalmology	1984	196
14769624	1351	Wassertheil-Smoller S	Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI).	Archives of internal medicine	2004	103
15159263	1351	Hu G	Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.	Archives of internal medicine	2004	123
15590763	1351	Foley RN	Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.	Journal of the American Society of Nephrology 	2005	165
18378618	1351	Schramm TK	Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.	Circulation	2008	72
19088353	1351	Barone BB	Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.	JAMA	2008	156
19131355	1351	Wizemann V	The mortality risk of overhydration in haemodialysis patients.	Nephrology, dialysis, transplantation 	2009	86
19221219	1351	Fung TT	Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women.	Circulation	2009	126
22465831	1351	Sadeghi N	Metformin use is associated with better survival of diabetic patients with pancreatic cancer.	Clinical cancer research 	2012	75
23802192	1351	Robinson BM	Worldwide, mortality risk is high soon after initiation of hemodialysis.	Kidney international	2014	21
12377295	1392	Tsigos C	Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress.	Journal of psychosomatic research	2002	278
21257974	1392	Stetler C	Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research.	Psychosomatic medicine	2011	116
25486982	1392	Gold PW	The organization of the stress system and its dysregulation in depressive illness.	Molecular psychiatry	2015	44
9490235	1401	Ridker PM	Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.	Circulation	1998	108
9655393	1401	Staels B	Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.	Nature	1998	144
9987089	1401	Zimmermann J	Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.	Kidney international	1999	125
10335721	1401	Harris TB	Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.	The American journal of medicine	1999	307
10591334	1401	Visser M	Elevated C-reactive protein levels in overweight and obese adults.	JAMA	1999	334
10807470	1401	Gottdiener JS	Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.	Journal of the American College of Cardiology	2000	198
10999830	1401	Bastard JP	Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.	The Journal of clinical endocrinology and metabolism	2000	129
11157411	1401	Geffken DF	Association between physical activity and markers of inflammation in a healthy elderly population.	American journal of epidemiology	2001	99
11434828	1401	Albert MA	Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.	JAMA	2001	174
11466099	1401	Pradhan AD	C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.	JAMA	2001	700
11574423	1401	Barzilay JI	The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study.	Diabetes	2001	88
11692019	1401	Rost NS	Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.	Stroke	2001	105
11744348	1401	Das UN	Is obesity an inflammatory condition?	Nutrition	2001	122
11864854	1401	Liu S	Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women.	The American journal of clinical nutrition	2002	95
11916939	1401	Stehouwer CD	Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.	Diabetes	2002	94
11978661	1401	Freeman DJ	C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.	Diabetes	2002	122
12021247	1401	Hundal RS	Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.	The Journal of clinical investigation	2002	144
12163427	1401	Haffner SM	Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.	Circulation	2002	90
12432042	1401	Ridker PM	Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.	The New England journal of medicine	2002	500
12551862	1401	Devaraj S	C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.	Circulation	2003	77
12576356	1401	Enright PL	The 6-min walk test: a quick measure of functional status in elderly adults.	Chest	2003	114
12684358	1401	Esposito K	Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.	JAMA	2003	222
12829649	1401	Duncan BB	Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study.	Diabetes	2003	200
12860911	1401	Sattar N	Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.	Circulation	2003	175
14871421	1401	Oberg BP	Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.	Kidney international	2004	127
14871914	1401	Jiang R	Body iron stores in relation to risk of type 2 diabetes in apparently healthy women.	JAMA	2004	99
15031312	1401	Tilvis RS	Predictors of cognitive decline and mortality of aged people over a 10-year period.	The journals of gerontology. Series A, Biological sciences and medical sciences	2004	90
15051634	1401	Ridker PM	Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.	Circulation	2004	70
15082700	1401	Pischon T	Plasma adiponectin levels and risk of myocardial infarction in men.	JAMA	2004	303
15136311	1401	Ford DE	Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey.	Archives of internal medicine	2004	94
15173056	1401	Willerson JT	Inflammation as a cardiovascular risk factor.	Circulation	2004	159
15173060	1401	Landmesser U	Endothelial function: a critical determinant in atherosclerosis?	Circulation	2004	114
15197140	1401	Esposito K	Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.	Circulation	2004	73
15197153	1401	Ridker PM	Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?	Circulation	2004	82
15201411	1401	Klein S	Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.	The New England journal of medicine	2004	113
15262830	1401	Selvin E	Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.	Circulation	2004	263
15447916	1401	Lopez-Garcia E	Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction.	The American journal of clinical nutrition	2004	141
15602020	1401	Pai JK	Inflammatory markers and the risk of coronary heart disease in men and women.	The New England journal of medicine	2004	233
15632335	1401	Dansinger ML	Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial.	JAMA	2005	214
15699278	1401	Desvarieux M	Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).	Circulation	2005	111
15817606	1401	Wannamethee SG	Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease.	European heart journal	2005	69
15827312	1401	Shlipak MG	Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.	JAMA	2005	152
16002815	1401	Fung TT	Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction.	The American journal of clinical nutrition	2005	118
16030277	1401	Ridker PM	Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.	JAMA	2005	136
16251239	1401	Fried LF	Kidney function as a predictor of noncardiovascular mortality.	Journal of the American Society of Nephrology 	2005	78
16377395	1401	Honda H	Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.	American journal of kidney diseases 	2006	72
16505242	1401	Devaraj S	Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes.	Diabetes	2006	84
16534530	1401	Kim CS	Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters.	International journal of obesity	2006	70
16600925	1401	Ma Y	Association between dietary fiber and serum C-reactive protein.	The American journal of clinical nutrition	2006	65
16835049	1401	Dubowsky SD	Diabetes, obesity, and hypertension may enhance associations between air pollution and markers of systemic inflammation.	Environmental health perspectives	2006	112
16894037	1401	Sattar N	Adiponectin and coronary heart disease: a prospective study and meta-analysis.	Circulation	2006	82
16952548	1401	Bekri S	Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH.	Gastroenterology	2006	88
17027526	1401	Fain JN	Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells.	Vitamins and hormones	2006	124
17040956	1401	Wang Y	Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.	Clinical chemistry	2007	91
17043079	1401	Fitzpatrick AL	Leukocyte telomere length and cardiovascular disease in the cardiovascular health study.	American journal of epidemiology	2007	200
17192343	1401	Samaras K	Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and corrected hypoadiponectinemia.	Diabetes care	2007	61
17242319	1401	Ranjit N	Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis.	Archives of internal medicine	2007	66
17277040	1401	Pittas AG	The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults.	Diabetes care	2007	141
17310862	1401	Punjabi NM	C-reactive protein is associated with sleep disordered breathing independent of adiposity.	Sleep	2007	59
17324119	1401	Savoia C	Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.	Clinical science	2007	72
17341558	1401	Balagopal P	Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation.	The Journal of clinical endocrinology and metabolism	2007	61
17429083	1401	Larsen CM	Interleukin-1-receptor antagonist in type 2 diabetes mellitus.	The New England journal of medicine	2007	415
17452738	1401	Uribarri J	Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging.	The journals of gerontology. Series A, Biological sciences and medical sciences	2007	82
17496352	1401	Mohan V	Epidemiology of type 2 diabetes: Indian scenario.	The Indian journal of medical research	2007	131
17531663	1401	Ridker PM	C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.	Journal of the American College of Cardiology	2007	119
17533210	1401	Wilson PW	Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.	Archives of internal medicine	2007	216
17576871	1401	Cao JJ	Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study.	Circulation	2007	65
17679132	1401	Pradhan AD	Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women.	The American journal of medicine	2007	56
17709633	1401	Pou KM	Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study.	Circulation	2007	196
17911176	1401	Laughlin GA	Low serum testosterone and mortality in older men.	The Journal of clinical endocrinology and metabolism	2008	119
17967770	1401	Mora S	Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms.	Circulation	2007	133
18175744	1401	Wolever TM	The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein.	The American journal of clinical nutrition	2008	51
18240558	1401	Ridker PM	Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity.	Nutrition reviews	2007	59
18285554	1401	Nair KS	Asian Indians have enhanced skeletal muscle mitochondrial capacity to produce ATP in association with severe insulin resistance.	Diabetes	2008	60
18413553	1401	Fung TT	Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women.	Archives of internal medicine	2008	170
18439548	1401	Ridker PM	Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study.	American journal of human genetics	2008	114
18452784	1401	Bahrami H	Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study.	Journal of the American College of Cardiology	2008	84
18480203	1401	Zethelius B	Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.	The New England journal of medicine	2008	179
18997196	1401	Ridker PM	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.	The New England journal of medicine	2008	930
19016938	1401	Nicklas BJ	Exercise training and plasma C-reactive protein and interleukin-6 in elderly people.	Journal of the American Geriatrics Society	2008	52
19088165	1401	Pittas AG	Association between serum osteocalcin and markers of metabolic phenotype.	The Journal of clinical endocrinology and metabolism	2009	88
19131384	1401	de Ruijter W	Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.	BMJ	2009	70
19153409	1401	Paynter NP	Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3.	Annals of internal medicine	2009	73
19245965	1401	Frankel DS	Resistin, adiponectin, and risk of heart failure the Framingham offspring study.	Journal of the American College of Cardiology	2009	59
19387353	1401	Triant VA	Association of C-reactive protein and HIV infection with acute myocardial infarction.	Journal of acquired immune deficiency syndromes	2009	99
19407273	1401	Fernandez-Egea E	Metabolic profile of antipsychotic-naive individuals with non-affective psychosis.	The British journal of psychiatry 	2009	52
19424218	1401	Mozaffarian D	Health effects of trans-fatty acids: experimental and observational evidence.	European journal of clinical nutrition	2009	60
19443637	1401	de Boer IH	25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification.	Journal of the American Society of Nephrology 	2009	69
19524346	1401	Gruenewald TL	Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study.	Social science and medicine	2009	53
19584191	1401	Nadeau KJ	Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity.	The Journal of clinical endocrinology and metabolism	2009	46
19695853	1401	Balducci S	Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss.	Nutrition, metabolism, and cardiovascular diseases 	2010	80
19820018	1401	Smith J	Effects of maternal surgical weight loss in mothers on intergenerational transmission of obesity.	The Journal of clinical endocrinology and metabolism	2009	58
20031199	1401	Emerging Risk Factors Collaboration.	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.	Lancet	2010	368
20097779	1401	Bertoni AG	Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA).	Diabetes care	2010	50
20417247	1401	Shelton RC	Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression.	Progress in neurobiology	2010	47
20421924	1401	Whincup PH	Early emergence of ethnic differences in type 2 diabetes precursors in the UK: the Child Heart and Health Study in England (CHASE Study).	PLoS medicine	2010	40
20538833	1401	Goicoechea M	Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.	Clinical journal of the American Society of Nephrology 	2010	124
20569726	1401	Soliman EZ	Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).	American heart journal	2010	46
20628408	1401	Velho S	Metabolically healthy obesity: different prevalences using different criteria.	European journal of clinical nutrition	2010	45
20876676	1401	Yu M	Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress.	Clinical journal of the American Society of Nephrology 	2011	41
20921964	1401	Harvie MN	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.	International journal of obesity	2011	75
20923483	1401	Ford ES	Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US.	Journal of diabetes	2010	96
21232666	1401	Stamatakis E	Screen-based entertainment time, all-cause mortality, and cardiovascular events: population-based study with ongoing mortality and hospital events follow-up.	Journal of the American College of Cardiology	2011	72
21349201	1401	Su G	Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes.	Cardiovascular diabetology	2011	41
21525259	1401	Azadbakht L	The Dietary Approaches to Stop Hypertension eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2 diabetic patients.	The Journal of nutrition	2011	40
21680719	1401	Tan ZS	Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study.	Diabetes care	2011	42
21792295	1401	Kones R	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.	Drug design, development and therapy	2011	39
21982649	1401	Ridker PM	Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).	American heart journal	2011	165
22412070	1401	de Koning L	Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men.	Circulation	2012	76
22414775	1401	Landi F	Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study.	Clinical nutrition	2012	61
22431676	1401	Kavousi M	Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.	Annals of internal medicine	2012	57
22492856	1401	Parrinello CM	Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women.	The Journal of infectious diseases	2012	41
22508708	1401	Hamer M	Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality.	The Journal of clinical endocrinology and metabolism	2012	79
22564993	1401	Bonanni B	Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.	Journal of clinical oncology 	2012	60
22658574	1401	Anderson AH	Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study.	American journal of kidney diseases 	2012	63
22708923	1401	Bartlett DB	The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection.	Aging cell	2012	31
22738663	1401	Yan S	The expanding burden of cardiometabolic risk in China: the China Health and Nutrition Survey.	Obesity reviews 	2012	40
22910756	1401	Yeboah J	Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.	JAMA	2012	143
23022122	1401	DeBoer MD	Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions.	Nutrition	2013	34
23034020	1401	Emerging Risk Factors Collaboration.	C-reactive protein, fibrinogen, and cardiovascular disease prediction.	The New England journal of medicine	2012	172
23129601	1401	Ridker PM	Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.	Circulation	2012	76
23141484	1401	Yamamoto S	Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.	Journal of the American College of Cardiology	2012	37
23143785	1401	Gupta SC	Therapeutic roles of curcumin: lessons learned from clinical trials.	The AAPS journal	2013	133
23264288	1401	Wang X	Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis.	Diabetes care	2013	74
23687099	1401	Neeland IJ	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.	Obesity	2013	48
23843750	1401	Stringhini S	Association of lifecourse socioeconomic status with chronic inflammation and type 2 diabetes risk: the Whitehall II prospective cohort study.	PLoS medicine	2013	27
24205846	1401	Coelho R	Childhood maltreatment and inflammatory markers: a systematic review.	Acta psychiatrica Scandinavica	2014	28
24284436	1401	Ley SH	Associations between red meat intake and biomarkers of inflammation and glucose metabolism in women.	The American journal of clinical nutrition	2014	22
24443059	1401	Aleksandrova K	Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.	Hepatology	2014	29
24559495	1401	Dogan MV	The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women.	BMC genomics	2014	53
24970784	1401	Dregan A	Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study.	Circulation	2014	25
25054777	1401	Freedman BI	APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.	Kidney international	2015	26
25133871	1401	Khandaker GM	Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study.	JAMA psychiatry	2014	49
25142571	1401	Irwin MR	Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial.	Sleep	2014	25
25341516	1401	Guarner V	Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease.	Interdisciplinary topics in gerontology	2015	22
25390655	1401	Willeit P	Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis.	PloS one	2014	25
25557209	1401	Karachaliou M	Association of trimester-specific gestational weight gain with fetal growth, offspring obesity, and cardiometabolic traits in early childhood.	American journal of obstetrics and gynecology	2015	20
25965853	1401	Dopico XC	Widespread seasonal gene expression reveals annual differences in human immunity and physiology.	Nature communications	2015	40
26729882	1401	Yang YC	Social relationships and physiological determinants of longevity across the human life span.	Proceedings of the National Academy of Sciences of the United States of America	2016	15
27013319	1401	Odegaard AO	Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes.	Cardiovascular diabetology	2016	16
27040132	1401	Yusuf S	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.	The New England journal of medicine	2016	24
15667933	1432	Tsuda M	Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia.	Trends in neurosciences	2005	183
16385087	1432	Isoda K	Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.	Arteriosclerosis, thrombosis, and vascular biology	2006	72
18285558	1432	Ali TK	Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes.	Diabetes	2008	61
18420487	1432	Busik JV	Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators.	Diabetes	2008	75
20089617	1432	Ma K	12-Lipoxygenase Products Reduce Insulin Secretion and {beta}-Cell Viability in Human Islets.	The Journal of clinical endocrinology and metabolism	2010	43
20110572	1432	Schwartz EA	Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation.	Arteriosclerosis, thrombosis, and vascular biology	2010	42
20957344	1432	Ali TK	Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury.	Diabetologia	2011	44
21144973	1432	Rajesh M	Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.	Journal of the American College of Cardiology	2010	56
21163347	1432	Henriksen EJ	Oxidative stress and the etiology of insulin resistance and type 2 diabetes.	Free radical biology and medicine	2011	80
22969168	1432	Lim AK	Inflammation in diabetic nephropathy.	Mediators of inflammation	2012	62
15788478	1471	Perkins BA	Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study.	Journal of the American Society of Nephrology 	2005	89
17329575	1471	Perkins BA	Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.	Journal of the American Society of Nephrology 	2007	105
19119287	1471	Stevens LA	Factors other than glomerular filtration rate affect serum cystatin C levels.	Kidney international	2009	113
20332356	1471	Ficociello LH	High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.	Diabetes care	2010	43
22762315	1471	Inker LA	Estimating glomerular filtration rate from serum creatinine and cystatin C.	The New England journal of medicine	2012	450
23423253	1471	Rule AD	Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease.	Kidney international	2013	30
23619125	1471	Grams ME	Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C-based estimates.	American journal of kidney diseases 	2013	28
1323143	1493	Lenschow DJ	Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.	Science	1992	176
16167085	1493	Bisikirska B	TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.	The Journal of clinical investigation	2005	90
21205883	1493	Steck AK	Genetics of type 1 diabetes.	Clinical chemistry	2011	40
25213377	1493	Kuehn HS	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.	Science	2014	83
25634360	1493	Rosenzwajg M	Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.	Journal of autoimmunity	2015	24
18414631	1628	Auchincloss AH	Associations between recent exposure to ambient fine particulate matter and blood pressure in the Multi-ethnic Study of Atherosclerosis (MESA).	Environmental health perspectives	2008	85
20511061	1628	Takiishi T	Vitamin D and diabetes.	Endocrinology and metabolism clinics of North America	2010	45
22088239	1628	Liu LS	2010 Chinese guidelines for the management of hypertension.	Zhonghua xin xue guan bing za zhi	2011	95
25775274	1628	Beveridge LA	Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data.	JAMA internal medicine	2015	35
8413456	1636	Lewis EJ	The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.	The New England journal of medicine	1993	490
9385294	1636	-	The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.	Archives of internal medicine	1997	445
10675071	1636	-	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.	Lancet	2000	322
10752702	1636	-	Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group.	Lancet	2000	96
11453706	1636	Jafar TH	Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.	Annals of internal medicine	2001	100
12020339	1636	Beckman JA	Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.	JAMA	2002	339
12788992	1636	Perkins BA	Regression of microalbuminuria in type 1 diabetes.	The New England journal of medicine	2003	147
15381652	1636	Dong M	Insights into causal pathways for ischemic heart disease: adverse childhood experiences study.	Circulation	2004	176
15516696	1636	Barnett AH	Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.	The New England journal of medicine	2004	109
16338452	1636	Casas JP	Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.	Lancet	2005	78
16760444	1636	Cooper WO	Major congenital malformations after first-trimester exposure to ACE inhibitors.	The New England journal of medicine	2006	115
17240286	1636	Elliott WJ	Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.	Lancet	2007	145
17765963	1636	Patel A	Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.	Lancet	2007	245
17984482	1636	Kunz R	Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.	Annals of internal medicine	2008	94
17984484	1636	Matchar DB	Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.	Annals of internal medicine	2008	63
18378520	1636	ONTARGET Investigators.	Telmisartan, ramipril, or both in patients at high risk for vascular events.	The New England journal of medicine	2008	420
18440425	1636	Xavier D	Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.	Lancet	2008	108
18707986	1636	Mann JF	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.	Lancet	2008	243
18757085	1636	Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators.	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.	Lancet	2008	132
19926893	1636	Mehdi UF	Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.	Journal of the American Society of Nephrology 	2009	69
20440277	1636	Ruggenenti P	The RAAS in the pathogenesis and treatment of diabetic nephropathy.	Nature reviews. Nephrology	2010	43
21544514	1636	Tseng CH	Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan.	Diabetologia	2011	35
21705121	1636	Fischer MJ	CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies.	American journal of kidney diseases 	2011	46
21872920	1636	Yusuf S	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.	Lancet	2011	128
22135311	1636	Vegter S	Sodium intake, ACE inhibition, and progression to ESRD.	Journal of the American Society of Nephrology 	2012	42
23100218	1636	Ruggenenti P	Mechanisms and treatment of CKD.	Journal of the American Society of Nephrology 	2012	34
24206457	1636	Fried LF	Combined angiotensin inhibition for the treatment of diabetic nephropathy.	The New England journal of medicine	2013	107
25300735	1636	Gilbert LK	Childhood adversity and adult chronic disease: an update from ten states and the District of Columbia, 2010.	American journal of preventive medicine	2015	18
25399731	1636	Torres VE	Angiotensin blockade in late autosomal dominant polycystic kidney disease.	The New England journal of medicine	2014	25
26009228	1636	Palmer SC	Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.	Lancet	2015	30
26268910	1636	de Zeeuw D	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.	The lancet. Diabetes and endocrinology	2015	21
12892317	1803	Lambeir AM	Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.	Critical reviews in clinical laboratory sciences	2003	110
16380482	1803	Segal MS	Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes.	Diabetes	2006	67
16517403	1803	Drucker DJ	The biology of incretin hormones.	Cell metabolism	2006	406
16816950	1803	Matikainen N	Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.	Diabetologia	2006	60
16912128	1803	Herman GA	Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.	The Journal of clinical endocrinology and metabolism	2006	81
17130196	1803	Aschner P	Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.	Diabetes care	2006	152
17130197	1803	Charbonnel B	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.	Diabetes care	2006	122
17157112	1803	Rosenstock J	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.	Clinical therapeutics	2006	91
17277036	1803	Bosi E	Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.	Diabetes care	2007	77
17300595	1803	Nauck MA	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.	Diabetes, obesity and metabolism	2007	117
17353295	1803	Wajchenberg BL	beta-cell failure in diabetes and preservation by clinical treatment.	Endocrine reviews	2007	142
17387446	1803	Fonseca V	Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.	Diabetologia	2007	66
17409288	1803	Dunning BE	The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.	Endocrine reviews	2007	79
17485570	1803	Goldstein BJ	Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.	Diabetes care	2007	103
17593236	1803	Hermansen K	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.	Diabetes, obesity and metabolism	2007	102
17933414	1803	Nonaka K	Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.	Diabetes research and clinical practice	2008	59
18425967	1803	Richter B	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.	The Cochrane database of systematic reviews	2008	54
18786299	1803	DeFronzo RA	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.	Current medical research and opinion	2008	82
18786605	1803	Holst JJ	The incretin system and its role in type 2 diabetes mellitus.	Molecular and cellular endocrinology	2009	75
19858063	1803	Rodbard HW	Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.	Endocrine practice 	2009	200
20075143	1803	Read PA	DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.	Circulation. Cardiovascular imaging	2010	42
20357375	1803	Fadini GP	The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.	Diabetes care	2010	63
20388897	1803	Phung OJ	Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.	JAMA	2010	75
20417856	1803	Pratley RE	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.	Lancet	2010	124
20580422	1803	Bergenstal RM	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.	Lancet	2010	126
21114605	1803	Taskinen MR	Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.	Diabetes, obesity and metabolism	2011	63
21205122	1803	Del Prato S	Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.	Diabetes, obesity and metabolism	2011	69
21208359	1803	Madsbad S	An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.	Diabetes, obesity and metabolism	2011	36
21334333	1803	Elashoff M	Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.	Gastroenterology	2011	127
21355967	1803	Pratley R	One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.	International journal of clinical practice	2011	50
21403054	1803	Bennett WL	Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.	Annals of internal medicine	2011	82
21593202	1803	Lamers D	Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.	Diabetes	2011	94
21672124	1803	Graefe-Mody U	Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).	Diabetes, obesity and metabolism	2011	39
21734003	1803	Drucker DJ	The safety of incretin-based therapies--review of the scientific evidence.	The Journal of clinical endocrinology and metabolism	2011	40
21781152	1803	Owens DR	Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.	Diabetic medicine 	2011	52
21812507	1803	Baetta R	Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.	Drugs	2011	39
21824266	1803	D'Alessio D	The role of dysregulated glucagon secretion in type 2 diabetes.	Diabetes, obesity and metabolism	2011	48
22106978	1803	Monami M	Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.	Current medical research and opinion	2011	41
22215383	1803	Monami M	DPP-4 inhibitors and lipids: systematic review and meta-analysis.	Advances in therapy	2012	38
22234149	1803	Johansen OE	Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.	Cardiovascular diabetology	2012	49
22323472	1803	Ussher JR	Cardiovascular biology of the incretin system.	Endocrine reviews	2012	96
22411919	1803	Karagiannis T	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.	BMJ	2012	69
22471248	1803	Deacon CF	Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.	Diabetes, obesity and metabolism	2012	32
22688551	1803	Rizzo MR	Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.	Diabetes care	2012	47
22703861	1803	Patil HR	Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.	The American journal of cardiology	2012	36
22745245	1803	Makdissi A	Sitagliptin exerts an antinflammatory action.	The Journal of clinical endocrinology and metabolism	2012	43
22748821	1803	Gallwitz B	2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.	Lancet	2012	69
22843705	1803	Kröller-Schön S	Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.	Cardiovascular research	2012	37
22925682	1803	Monami M	Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.	Diabetes, obesity and metabolism	2013	44
23033241	1803	McGill JB	Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.	Diabetes care	2013	35
23035207	1803	Shigeta T	Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions.	Circulation	2012	38
23296071	1803	Scheen AJ	Cardiovascular effects of gliptins.	Nature reviews. Cardiology	2013	27
23344728	1803	Kim YG	Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.	Diabetologia	2013	53
23386232	1803	Matsubara J	Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.	Circulation journal 	2013	33
23440284	1803	Singh S	Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.	JAMA internal medicine	2013	61
23449634	1803	Rosenstock J	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.	Diabetes and vascular disease research	2013	27
23525426	1803	Ayaori M	Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.	Journal of the American Heart Association	2013	31
23715753	1803	Gough SC	Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.	Diabetes care	2013	28
23815104	1803	Curkendall SM	Predictors of medication adherence in patients with type 2 diabetes mellitus.	Current medical research and opinion	2013	27
23818527	1803	Drucker DJ	Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.	Diabetes	2013	57
23932846	1803	Aroor AR	Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.	Metabolism	2013	41
23992601	1803	Scirica BM	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.	The New England journal of medicine	2013	377
23992602	1803	White WB	Alogliptin after acute coronary syndrome in patients with type 2 diabetes.	The New England journal of medicine	2013	294
24144654	1803	Jabbour SA	Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.	Diabetes care	2014	42
24198301	1803	Turner LW	Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.	Diabetes care	2014	25
24225429	1803	Fujita H	DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.	Endocrine journal	2014	22
24375052	1803	Muskiet MH	The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?	Nature reviews. Nephrology	2014	21
24623020	1803	Hampp C	Use of antidiabetic drugs in the U.S., 2003-2012.	Diabetes care	2014	33
24732974	1803	DeMarco VG	The pathophysiology of hypertension in patients with obesity.	Nature reviews. Endocrinology	2014	43
24736555	1803	Li L	Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.	BMJ	2014	34
24750644	1803	Wu S	Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.	Cardiovascular therapeutics	2014	28
24793580	1803	Monami M	Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.	Nutrition, metabolism, and cardiovascular diseases 	2014	30
24855202	1803	Ussher JR	Cardiovascular actions of incretin-based therapies.	Circulation research	2014	40
24998080	1803	Weir DL	Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.	JACC. Heart failure	2014	26
25074318	1803	Nakamura K	DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.	Cardiovascular diabetology	2014	23
25528528	1803	Savarese G	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.	International journal of cardiology	2015	17
25765696	1803	Zannad F	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.	Lancet	2015	67
26009231	1803	Gilbert RE	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.	Lancet	2015	29
26052984	1803	Green JB	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.	The New England journal of medicine	2015	183
26063450	1803	Ferrannini E	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.	European heart journal	2015	17
26112890	1803	Fadini GP	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.	European heart journal	2015	16
26457538	1803	Ou SM	Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.	Annals of internal medicine	2015	17
26489970	1803	Nauck M	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.	Diabetes, obesity and metabolism	2016	14
26628419	1803	Mita T	Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).	Diabetes care	2016	14
26822324	1803	Mita T	Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.	Diabetes care	2016	14
26888822	1803	Li L	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.	BMJ	2016	15
27007958	1803	Filion KB	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.	The New England journal of medicine	2016	19
27434443	1803	Palmer SC	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.	JAMA	2016	14
14990351	1906	Gladwin MT	The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.	Free radical biology and medicine	2004	73
16618833	1906	Kim JA	Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.	Circulation	2006	269
17065335	1906	Schmid H	Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy.	Diabetes	2006	104
17179929	1906	Rask-Madsen C	Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes.	Nature clinical practice. Endocrinology and metabolism	2007	104
19149564	1906	Potenza MA	Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets.	Current medicinal chemistry	2009	61
19903865	1906	Chen S	Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells.	American journal of physiology. Endocrinology and metabolism	2010	49
22409294	1906	Zhou J	Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy.	Current eye research	2012	33
21189092	1956	de Boer RA	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.	Annals of medicine	2011	74
21338849	1956	Stevens LA	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP).	American journal of kidney diseases 	2011	38
21355053	1956	Rosolowsky ET	Risk for ESRD in type 1 diabetes remains high despite renoprotection.	Journal of the American Society of Nephrology 	2011	52
22112968	1956	He X	Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.	Annals of oncology 	2012	49
23687356	1956	Rhee EP	A combined epidemiologic and metabolomic approach improves CKD prediction.	Journal of the American Society of Nephrology 	2013	40
24429397	1956	Niewczas MA	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.	Kidney international	2014	27
24722445	1956	de Zeeuw D	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.	Journal of the American Society of Nephrology 	2014	36
24970885	1956	Navarro-González JF	Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.	Journal of the American Society of Nephrology 	2015	18
25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
25589610	1956	Schanstra JP	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.	Journal of the American Society of Nephrology 	2015	21
25677388	1956	Banerjee T	High Dietary Acid Load Predicts ESRD among Adults with CKD.	Journal of the American Society of Nephrology 	2015	17
25726255	1956	Higuchi C	Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes.	Metabolism	2015	20
25805821	1956	Kaszuba K	N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
27539604	1956	Heerspink HJ	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.	Journal of the American Society of Nephrology 	2017	13
15247477	2056	Leist M	Derivatives of erythropoietin that are tissue protective but not erythropoietic.	Science	2004	157
17267743	2056	Inaba M	Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection.	Journal of the American Society of Nephrology 	2007	75
17656472	2056	Foley RN	End-stage renal disease in the United States: an update from the United States Renal Data System.	Journal of the American Society of Nephrology 	2007	88
18458324	2056	Tong Z	Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
24158761	2056	Bachman E	Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point.	The journals of gerontology. Series A, Biological sciences and medical sciences	2014	24
25535770	2056	Salvagno GL	Red blood cell distribution width: A simple parameter with multiple clinical applications.	Critical reviews in clinical laboratory sciences	2015	34
16641093	2167	Tuncman G	A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease.	Proceedings of the National Academy of Sciences of the United States of America	2006	60
8353913	2244	Newman AB	Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group.	Circulation	1993	156
10657556	2244	Yudkin JS	Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?	Atherosclerosis	2000	214
15840727	2244	Steptoe A	Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes.	Proceedings of the National Academy of Sciences of the United States of America	2005	109
16723443	2244	Wong TY	Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA).	Investigative ophthalmology and visual science	2006	92
17485598	2244	Roman MJ	Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study.	Hypertension	2007	132
18328671	2244	Suarez EC	Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity.	Brain, behavior, and immunity	2008	64
20943795	2244	Mozaffarian D	Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes.	The American journal of clinical nutrition	2010	43
22347441	2244	Pinto Pereira SM	Sedentary behaviour and biomarkers for cardiovascular disease and diabetes in mid-life: the role of television-viewing and sitting at work.	PloS one	2012	39
22385985	2244	Adinolfi LE	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.	Atherosclerosis	2012	35
23755138	2244	Menzaghi C	Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes.	PloS one	2014	21
23791463	2244	Miller J	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort.	Respiratory medicine	2013	37
15653324	2475	Harrington LS	Restraining PI3K: mTOR signalling goes back to the membrane.	Trends in biochemical sciences	2005	125
15681023	2475	Luo Z	AMPK, the metabolic syndrome and cancer.	Trends in pharmacological sciences	2005	109
15718470	2475	Sarbassov DD	Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.	Science	2005	1945
15878852	2475	Long X	Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency.	The Journal of biological chemistry	2005	110
16226444	2475	Sarbassov DD	Growing roles for the mTOR pathway.	Current opinion in cell biology	2005	507
16354680	2475	Tzatsos A	Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation.	Molecular and cellular biology	2006	123
16753575	2475	Um SH	Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.	Cell metabolism	2006	205
17275731	2475	Tsang CK	Targeting mammalian target of rapamycin (mTOR) for health and diseases.	Drug discovery today	2007	106
17329620	2475	Krebs M	The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man.	Diabetes	2007	58
17463046	2475	Roos S	Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth.	The Journal of physiology	2007	68
17666010	2475	Tremblay F	Role of dietary proteins and amino acids in the pathogenesis of insulin resistance.	Annual review of nutrition	2007	58
18006825	2475	Dowling RJ	Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.	Cancer research	2007	250
18460336	2475	Gulati P	Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.	Cell metabolism	2008	120
18614546	2475	Rosner M	Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.	Human molecular genetics	2008	71
19771169	2475	Balgi AD	Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.	PloS one	2009	108
19822355	2475	Cantrell LA	Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.	Gynecologic oncology	2010	65
19875810	2475	Lieberthal W	The role of the mammalian target of rapamycin (mTOR) in renal disease.	Journal of the American Society of Nephrology 	2009	78
19948145	2475	Laplante M	An emerging role of mTOR in lipid biosynthesis.	Current biology 	2009	144
20386866	2475	Ost A	Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes.	Molecular medicine	2010	57
20388847	2475	Rozengurt E	Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.	Clinical cancer research 	2010	71
20491627	2475	Zhou H	The complexes of mammalian target of rapamycin.	Current protein and peptide science	2010	42
20656475	2475	Jalving M	Metformin: taking away the candy for cancer?	European journal of cancer	2010	92
20810672	2475	Memmott RM	Metformin prevents tobacco carcinogen--induced lung tumorigenesis.	Cancer prevention research	2010	129
21157483	2475	Zoncu R	mTOR: from growth signal integration to cancer, diabetes and ageing.	Nature reviews. Molecular cell biology	2011	1188
21269838	2475	Howell JJ	mTOR couples cellular nutrient sensing to organismal metabolic homeostasis.	Trends in endocrinology and metabolism	2011	107
21284988	2475	Kim S	Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase.	Cell metabolism	2011	43
21470407	2475	Dowling RJ	Understanding the benefit of metformin use in cancer treatment.	BMC medicine	2011	88
21606591	2475	Gödel M	Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.	The Journal of clinical investigation	2011	124
21840335	2475	Speakman JR	Caloric restriction.	Molecular aspects of medicine	2011	138
22017684	2475	Inoki K	AMPK and mTOR in cellular energy homeostasis and drug targets.	Annual review of pharmacology and toxicology	2012	138
22065737	2475	Shin S	Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
22408252	2475	Tan SH	Induction of autophagy by palmitic acid via protein kinase C-mediated signaling pathway independent of mTOR (mammalian target of rapamycin).	The Journal of biological chemistry	2012	41
22500211	2475	Song CW	Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.	Scientific reports	2012	62
22500797	2475	Laplante M	mTOR signaling in growth control and disease.	Cell	2012	1760
22618766	2475	Barzilai N	The critical role of metabolic pathways in aging.	Diabetes	2012	101
23061800	2475	Passtoors WM	Gene expression analysis of mTOR pathway: association with human longevity.	Aging cell	2013	32
23150676	2475	Jansson N	Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies.	The Journal of clinical endocrinology and metabolism	2013	43
23165769	2475	Rosario FJ	Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells.	The Journal of physiology	2013	35
23460185	2475	Alayev A	mTOR signaling for biological control and cancer.	Journal of cellular physiology	2013	34
23641065	2475	Laplante M	Regulation of mTORC1 and its impact on gene expression at a glance.	Journal of cell science	2013	128
23694989	2475	Kim SG	Nutrient regulation of the mTOR complex 1 signaling pathway.	Molecules and cells	2013	56
23708729	2475	Ryter SW	Autophagy: a critical regulator of cellular metabolism and homeostasis.	Molecules and cells	2013	43
23881200	2475	Barlow AD	Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms.	Diabetes	2013	28
24024901	2475	Santulli G	Tailoring mTOR-based therapy: molecular evidence and clinical challenges.	Pharmacogenomics	2013	27
24055102	2475	Lee JH	Sestrins orchestrate cellular metabolism to attenuate aging.	Cell metabolism	2013	53
24336084	2475	Blagosklonny MV	TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.	Cell death and disease	2013	32
24508508	2475	Li J	Rapamycin: one drug, many effects.	Cell metabolism	2014	66
24556859	2475	Bernal-Mizrachi E	Human β-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map.	Diabetes	2014	43
24685370	2475	Kaplan B	Strategies for the management of adverse events associated with mTOR inhibitors.	Transplantation reviews	2014	23
24899720	2475	Caccamo A	Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.	The Journal of neuroscience 	2014	30
25253086	2475	Jia G	Overnutrition, mTOR signaling, and cardiovascular diseases.	American journal of physiology. Regulatory, integrative and comparative physiology	2014	25
25282103	2475	Wood AR	Defining the role of common variation in the genomic and biological architecture of adult human height.	Nature genetics	2014	268
25554914	2475	Albert V	mTOR signaling in cellular and organismal energetics.	Current opinion in cell biology	2015	49
25867026	2475	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	18
25902704	2475	Longo VD	Interventions to Slow Aging in Humans: Are We Ready?	Aging cell	2015	58
27748764	2475	Kim LC	mTORC1 and mTORC2 in cancer and the tumor microenvironment.	Oncogene	2017	10
28283069	2475	Saxton RA	mTOR Signaling in Growth, Metabolism, and Disease.	Cell	2017	27
8666144	2571	Verge CF	Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.	Diabetes	1996	131
9054945	2571	Pugliese A	The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.	Nature genetics	1997	162
18843118	2571	Ludvigsson J	GAD treatment and insulin secretion in recent-onset type 1 diabetes.	The New England journal of medicine	2008	123
20699420	2571	Keenan HA	Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.	Diabetes	2010	92
21714999	2571	Wherrett DK	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.	Lancet	2011	77
17595272	2572	Writing Group for the SEARCH for Diabetes in Youth Study Group.	Incidence of diabetes in youth in the United States.	JAMA	2007	267
19120261	2572	TEDDY Study Group.	The Environmental Determinants of Diabetes in the Young (TEDDY) Study.	Annals of the New York Academy of Sciences	2008	60
19741189	2572	Orban T	Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.	Diabetes care	2009	82
22296077	2572	Ludvigsson J	GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.	The New England journal of medicine	2012	60
22441569	2572	Parikka V	Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.	Diabetologia	2012	37
23780460	2572	Ziegler AG	Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.	JAMA	2013	102
8405741	2641	Nauck MA	Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.	Diabetologia	1993	130
8423228	2641	Nauck MA	Preserved incretin activity of glucagon-like peptide 1 7-36 amide but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.	The Journal of clinical investigation	1993	212
10794683	2641	Knudsen LB	Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.	Journal of medicinal chemistry	2000	102
11246881	2641	Vilsbøll T	Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.	Diabetes	2001	139
11502801	2641	Toft-Nielsen MB	Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.	The Journal of clinical endocrinology and metabolism	2001	135
11897280	2641	Zander M	Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.	Lancet	2002	188
11935150	2641	Agersø H	The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.	Diabetologia	2002	83
12540611	2641	Kjems LL	The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.	Diabetes	2003	89
12554744	2641	Drucker DJ	Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.	Molecular endocrinology	2003	85
12788877	2641	Vilsbøll T	Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.	The Journal of clinical endocrinology and metabolism	2003	89
12960095	2641	Farilla L	Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.	Endocrinology	2003	113
14981009	2641	Nikolaidis LA	Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.	Circulation	2004	175
15111485	2641	Degn KB	One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.	Diabetes	2004	71
15271645	2641	Holst JJ	Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.	American journal of physiology. Endocrinology and metabolism	2004	85
15273546	2641	Rubino F	The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism.	Annals of surgery	2004	92
15353407	2641	Nyström T	Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.	American journal of physiology. Endocrinology and metabolism	2004	136
16219666	2641	Theodorakis MJ	Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.	American journal of physiology. Endocrinology and metabolism	2006	72
17174230	2641	Sokos GG	Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.	Journal of cardiac failure	2006	122
17416796	2641	Laferrère B	Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes.	Diabetes care	2007	117
17711996	2641	Basu A	Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.	American journal of physiology. Endocrinology and metabolism	2007	60
17715056	2641	Parthier C	Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor.	Proceedings of the National Academy of Sciences of the United States of America	2007	84
17895322	2641	Goldfine AB	Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal.	The Journal of clinical endocrinology and metabolism	2007	62
17994216	2641	Parnaud G	Proliferation of sorted human and rat beta cells.	Diabetologia	2008	83
18057091	2641	Vollmer K	Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.	Diabetes	2008	74
18239636	2641	Rodieux F	Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release.	Obesity	2008	69
18393659	2641	Kellett GL	Sugar absorption in the intestine: the role of GLUT2.	Annual review of nutrition	2008	68
18782641	2641	Drucker DJ	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.	Lancet	2008	200
19037628	2641	Højberg PV	Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.	Diabetologia	2009	45
19289857	2641	Zinman B	Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).	Diabetes care	2009	182
19372197	2641	Thaler JP	Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery.	Endocrinology	2009	84
19515413	2641	Buse JB	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).	Lancet	2009	299
19638921	2641	Peterli R	Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial.	Annals of surgery	2009	88
19930006	2641	Jendle J	Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.	Diabetes, obesity and metabolism	2009	46
20130660	2641	Tarini J	The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects.	Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme	2010	45
20215461	2641	Buse JB	DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.	Diabetes care	2010	56
20871975	2641	Nauck MA	Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?	Diabetologia	2011	78
20876708	2641	Musso G	Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?	Diabetes care	2010	105
20929995	2641	Best JH	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.	Diabetes care	2011	55
21205128	2641	Garber A	Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.	Diabetes, obesity and metabolism	2011	39
21209033	2641	Hegedüs L	GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.	The Journal of clinical endocrinology and metabolism	2011	38
21307137	2641	Blevins T	DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.	The Journal of clinical endocrinology and metabolism	2011	71
21430088	2641	Nauck MA	Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.	Diabetes	2011	53
21647189	2641	Barrera JG	GLP-1 and energy balance: an integrated model of short-term and long-term control.	Nature reviews. Endocrinology	2011	53
21697254	2641	DeFronzo RA	Preservation of β-cell function: the key to diabetes prevention.	The Journal of clinical endocrinology and metabolism	2011	53
21868791	2641	Salehi M	Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans.	Diabetes	2011	67
21975753	2641	Shyangdan DS	Glucagon-like peptide analogues for type 2 diabetes mellitus.	The Cochrane database of systematic reviews	2011	36
22000927	2641	De Silva A	The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans.	Cell metabolism	2011	40
22029981	2641	Sumithran P	Long-term persistence of hormonal adaptations to weight loss.	The New England journal of medicine	2011	133
22538359	2641	Dirksen C	Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.	Diabetologia	2012	35
22899902	2641	Suzuki K	Obesity and appetite control.	Experimental diabetes research	2012	30
22915024	2641	Rodgers RJ	Anti-obesity drugs: past, present and future.	Disease models and mechanisms	2012	45
22945360	2641	Meier JJ	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.	Nature reviews. Endocrinology	2012	101
22965295	2641	Marchetti P	A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.	Diabetologia	2012	32
22968072	2641	Jiménez A	Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects.	Annals of surgery	2012	31
23141817	2641	Buse JB	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.	Lancet	2013	83
23183535	2641	Thatava T	Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells.	Molecular therapy 	2013	26
23187122	2641	Bradley D	Gastric bypass and banding equally improve insulin sensitivity and β cell function.	The Journal of clinical investigation	2012	52
23377698	2641	Calanna S	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.	Diabetologia	2013	29
23649520	2641	Jørgensen NB	Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.	Diabetes	2013	44
23812094	2641	Wadden TA	Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.	International journal of obesity	2013	37
24315990	2641	Salehi M	Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.	Gastroenterology	2014	22
24323912	2641	van Bloemendaal L	Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.	The Journal of endocrinology	2014	27
24988476	2641	Napolitano A	Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.	PloS one	2014	28
25018121	2641	Dungan KM	Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.	Lancet	2014	52
25190523	2641	Gough SC	Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.	The lancet. Diabetes and endocrinology	2014	35
25220191	2641	Eng C	Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.	Lancet	2014	32
25500202	2641	Chambers ES	Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.	Gut	2015	48
26132939	2641	Pi-Sunyer X	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.	The New England journal of medicine	2015	53
26394161	2641	Armstrong MJ	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.	Journal of hepatology	2016	13
27295427	2641	Marso SP	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.	The New England journal of medicine	2016	130
27633186	2641	Marso SP	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.	The New England journal of medicine	2016	54
15016359	2645	Kamata K	Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.	Structure	2004	94
17327436	2645	Winckler W	Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes.	Diabetes	2007	68
18556336	2645	Vaxillaire M	The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population.	Diabetes	2008	53
18726182	2645	Iynedjian PB	Molecular physiology of mammalian glucokinase.	Cellular and molecular life sciences 	2009	77
19373249	2645	Matschinsky FM	Assessing the potential of glucokinase activators in diabetes therapy.	Nature reviews. Drug discovery	2009	90
19643913	2645	Beer NL	The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.	Human molecular genetics	2009	97
19790256	2645	Osbak KK	Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.	Human mutation	2009	75
20499044	2645	Shields BM	Maturity-onset diabetes of the young (MODY): how many cases are we missing?	Diabetologia	2010	70
21459328	2645	Porat S	Control of pancreatic β cell regeneration by glucose metabolism.	Cell metabolism	2011	108
26577716	2645	Ohn JH	10-year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study.	The lancet. Diabetes and endocrinology	2016	16
12808136	2688	Stump CS	Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts.	Proceedings of the National Academy of Sciences of the United States of America	2003	101
16894525	2688	Gurney JG	Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia.	Cancer	2006	61
19240267	2688	Møller N	Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.	Endocrine reviews	2009	133
20584998	2688	Tong J	Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans.	Diabetes	2010	77
21079616	2688	Fiorenza CG	Lipodystrophy: pathophysiology and advances in treatment.	Nature reviews. Endocrinology	2011	39
21464293	2688	Chou SH	Leptin is an effective treatment for hypothalamic amenorrhea.	Proceedings of the National Academy of Sciences of the United States of America	2011	44
21791620	2688	Mantzoros CS	Leptin in human physiology and pathophysiology.	American journal of physiology. Endocrinology and metabolism	2011	88
22699302	2688	Garcia JM	Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.	Supportive care in cancer 	2013	27
23568441	2688	Berryman DE	The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations.	Nature reviews. Endocrinology	2013	30
20395504	2690	Fontana L	Extending healthy life span--from yeast to humans.	Science	2010	665
21325617	2690	Guevara-Aguirre J	Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans.	Science translational medicine	2011	174
21226820	2695	Tremblay AJ	Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.	Diabetes, obesity and metabolism	2011	39
21984584	2695	Christensen M	Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.	Diabetes	2011	37
22134839	2695	Beysen C	Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.	Diabetologia	2012	31
23684623	2695	Campbell JE	Pharmacology, physiology, and mechanisms of incretin hormone action.	Cell metabolism	2013	128
24018562	2695	Hodson DJ	Lipotoxicity disrupts incretin-regulated human β cell connectivity.	The Journal of clinical investigation	2013	42
12469359	2740	Straub SG	Glucose-stimulated signaling pathways in biphasic insulin secretion.	Diabetes/metabolism research and reviews	2002	84
18162504	2740	Muscelli E	Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.	Diabetes	2008	64
18287102	2740	Runge S	Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.	The Journal of biological chemistry	2008	101
18430778	2740	Laferrère B	Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes.	The Journal of clinical endocrinology and metabolism	2008	137
19317822	2740	Marre M	Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).	Diabetic medicine 	2009	172
19363506	2740	Cummings DE	Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery.	International journal of obesity	2009	50
19442172	2740	Cani PD	The role of the gut microbiota in energy metabolism and metabolic disease.	Current pharmaceutical design	2009	138
19808921	2740	Brown RJ	Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion.	Diabetes care	2009	48
20029383	2740	Kashyap SR	Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes.	International journal of obesity	2010	56
20452396	2740	Erdogdu O	Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.	Molecular and cellular endocrinology	2010	52
21844879	2740	Astrup A	Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.	International journal of obesity	2012	86
22236411	2740	Vilsbøll T	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.	BMJ	2012	118
22338093	2740	Nyborg NC	The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.	Diabetes	2012	31
22432104	2740	Fonseca VA	Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).	Diabetes care	2012	41
22564709	2740	Seino Y	Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).	Diabetes, obesity and metabolism	2012	57
23433305	2740	Wang B	Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.	Diabetes, obesity and metabolism	2013	28
23999914	2740	Hölscher C	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.	The Journal of endocrinology	2014	28
24467746	2740	Pyke C	GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.	Endocrinology	2014	53
24742660	2740	Nauck M	Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).	Diabetes care	2014	36
24842985	2740	Umpierrez G	Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).	Diabetes care	2014	34
24879836	2740	Wysham C	Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).	Diabetes care	2014	41
24898300	2740	Rosenstock J	Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.	Diabetes care	2014	29
25071023	2740	van Bloemendaal L	GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.	Diabetes	2014	35
25677912	2740	Færch K	GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.	Diabetes	2015	16
26089386	2740	Giorgino F	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).	Diabetes care	2015	16
26630143	2740	Pfeffer MA	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.	The New England journal of medicine	2015	80
26769791	2740	Sharma M	Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study.	BMJ open	2016	17
11438497	2875	Dixon JB	Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.	Gastroenterology	2001	176
12512031	2875	Ruhl CE	Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.	Gastroenterology	2003	118
12809815	2875	Clark JM	The prevalence and etiology of elevated aminotransferase levels in the United States.	The American journal of gastroenterology	2003	255
14512888	2875	Neuschwander-Tetri BA	Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.	Hepatology	2003	99
16682043	2875	Schindhelm RK	Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.	Atherosclerosis	2007	72
17595248	2875	Kotronen A	Liver fat in the metabolic syndrome.	The Journal of clinical endocrinology and metabolism	2007	70
18384521	2875	Leite NC	Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.	Liver international 	2009	76
18752331	2875	Fracanzani AL	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.	Hepatology	2008	95
18945255	2875	Loomba R	Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.	Alimentary pharmacology and therapeutics	2009	48
19010326	2875	Goessling W	Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.	Gastroenterology	2008	61
19131466	2875	Fraser A	Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis.	Diabetes care	2009	71
19523535	2875	Shah AG	Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.	Clinical gastroenterology and hepatology 	2009	84
20858492	2875	Williams CD	Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.	Gastroenterology	2011	346
22183689	2875	Lomonaco R	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.	Hepatology	2012	52
22271511	2875	Kim D	Nonalcoholic fatty liver disease is associated with coronary artery calcification.	Hepatology	2012	55
23355498	2875	Loomba R	Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.	American journal of epidemiology	2013	25
24316260	2875	Lambert JE	Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.	Gastroenterology	2014	63
25776943	2875	Guo K	Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals.	Obesity	2015	15
25873639	2875	Kwok R	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.	Gut	2016	13
26171685	2875	Koehler EM	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.	Hepatology	2016	11
26667191	2875	Ballestri S	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.	Journal of gastroenterology and hepatology	2016	25
11473047	3077	Marchesini G	Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.	Diabetes	2001	377
11812557	3077	Beutler E	Penetrance of 845G--&amp;gt; A (C282Y) HFE hereditary haemochromatosis mutation in the USA.	Lancet	2002	114
12105842	3077	Bugianesi E	Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.	Gastroenterology	2002	247
15858186	3077	Adams PC	Hemochromatosis and iron-overload screening in a racially diverse population.	The New England journal of medicine	2005	132
18252895	3117	Erlich H	HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families.	Diabetes	2008	165
20798335	3117	Noble JA	HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium.	Diabetes	2010	42
8072542	3119	Davies JL	A genome-wide search for human type 1 diabetes susceptibility genes.	Nature	1994	174
14519706	3119	Ziegler AG	Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies.	JAMA	2003	95
17244711	3119	Nelson JL	Maternal microchimerism in peripheral blood in type 1 diabetes and pancreatic islet beta cell microchimerism.	Proceedings of the National Academy of Sciences of the United States of America	2007	60
18814906	3119	Näntö-Salonen K	Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.	Lancet	2008	74
19522996	3119	Erkkola M	Maternal vitamin D intake during pregnancy is inversely associated with asthma and allergic rhinitis in 5-year-old children.	Clinical and experimental allergy 	2009	73
24550192	3119	Kallionpää H	Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility.	Diabetes	2014	27
15889096	3126	Kent SC	Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.	Nature	2005	110
15900004	3126	Norris JM	Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease.	JAMA	2005	73
21564455	3126	Hagopian WA	The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants.	Pediatric diabetes	2011	48
24988556	3126	Liu E	Risk of pediatric celiac disease according to HLA haplotype and country.	The New England journal of medicine	2014	43
25660258	3126	Krischer JP	The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study.	Diabetologia	2015	26
8945471	3172	Yamagata K	Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1)	Nature	1996	210
14988562	3172	Odom DT	Control of pancreas and liver gene expression by HNF transcription factors.	Science	2004	407
18301398	3172	Murphy R	Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes.	Nature clinical practice. Endocrinology and metabolism	2008	83
19440305	3172	Yuan X	Identification of an endogenous ligand bound to a native orphan nuclear receptor.	PloS one	2009	67
23485969	3172	Chandra V	Multidomain integration in the structure of the HNF-4α nuclear receptor complex.	Nature	2013	39
25646437	3172	Santiago JA	Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
2195544	3375	Westermark P	Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.	Proceedings of the National Academy of Sciences of the United States of America	1990	148
3317417	3375	Cooper GJ	Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.	Proceedings of the National Academy of Sciences of the United States of America	1987	172
8152488	3375	Lorenzo A	Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.	Nature	1994	157
15321714	3375	Knight JD	Phospholipid catalysis of diabetic amyloid assembly.	Journal of molecular biology	2004	103
17475933	3375	Huang CJ	High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes.	Diabetes	2007	127
17501667	3375	Hofbauer LC	Osteoporosis in patients with diabetes mellitus.	Journal of bone and mineral research 	2007	84
17979302	3375	Luca S	Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR.	Biochemistry	2007	153
18408164	3375	Engel MF	Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane.	Proceedings of the National Academy of Sciences of the United States of America	2008	106
18442979	3375	Apostolidou M	Structure of alpha-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding.	The Journal of biological chemistry	2008	62
18556473	3375	Wiltzius JJ	Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin).	Protein science 	2008	76
19208933	3375	Abedini A	A role for helical intermediates in amyloid formation by natively unfolded polypeptides?	Physical biology	2009	57
19244249	3375	Patil SM	Dynamic alpha-helix structure of micelle-bound human amylin.	The Journal of biological chemistry	2009	49
19346479	3375	Shim SH	Two-dimensional IR spectroscopy and isotope labeling defines the pathway of amyloid formation with residue-specific resolution.	Proceedings of the National Academy of Sciences of the United States of America	2009	86
19647750	3375	Williamson JA	Helix stabilization precedes aqueous and bilayer-catalyzed fiber formation in islet amyloid polypeptide.	Journal of molecular biology	2009	50
20042670	3375	Gurlo T	Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway.	The American journal of pathology	2010	59
20182863	3375	Zraika S	Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?	Diabetologia	2010	45
20609969	3375	Diamant M	Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.	Lancet	2010	88
21138825	3375	Buse JB	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.	Annals of internal medicine	2011	93
21742788	3375	Westermark P	Islet amyloid polypeptide, islet amyloid, and diabetes mellitus.	Physiological reviews	2011	152
21818468	3375	DeToma AS	Misfolded proteins in Alzheimer's disease and type II diabetes.	Chemical Society reviews	2012	49
21916515	3375	Wang L	2DIR spectroscopy of human amylin fibrils reflects stable β-sheet structure.	Journal of the American Chemical Society	2011	35
21942864	3375	Brender JR	Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective.	Accounts of chemical research	2012	63
22187437	3375	Bedrood S	Fibril structure of human islet amyloid polypeptide.	The Journal of biological chemistry	2012	34
22683137	3375	Gallwitz B	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.	Lancet	2012	34
23794448	3375	Jackson K	Amylin deposition in the brain: A second amyloid in Alzheimer disease?	Annals of neurology	2013	51
24218609	3375	Buchanan LE	Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet.	Proceedings of the National Academy of Sciences of the United States of America	2013	36
24374217	3375	Kameswaran V	Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets.	Cell metabolism	2014	52
25036705	3375	Kim J	Amyloidogenic peptide oligomer accumulation in autophagy-deficient β cells induces diabetes.	The Journal of clinical investigation	2014	24
11923038	3383	Nappo F	Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.	Journal of the American College of Cardiology	2002	90
15113816	3383	Meigs JB	Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus.	JAMA	2004	128
17112620	3383	Giulietti A	Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory.	Diabetes research and clinical practice	2007	58
17182639	3383	O'Neill MS	Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility.	Occupational and environmental medicine	2007	77
19118698	3383	Funatsu H	Association of vitreous inflammatory factors with diabetic macular edema.	Ophthalmology	2009	52
21448265	3383	Meijer K	Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages.	PloS one	2011	52
24335073	3383	Lutty GA	Effects of diabetes on the eye.	Investigative ophthalmology and visual science	2013	26
11679420	3479	Goran MI	Longitudinal study on pubertal insulin resistance.	Diabetes	2001	112
11694656	3479	Giovannucci E	Insulin, insulin-like growth factors and colon cancer: a review of the evidence.	The Journal of nutrition	2001	200
12360255	3479	De Meyts P	Structural biology of insulin and IGF1 receptors: implications for drug design.	Nature reviews. Drug discovery	2002	126
15069117	3479	Ma J	A prospective study of plasma C-peptide and colorectal cancer risk in men.	Journal of the National Cancer Institute	2004	78
17906644	3479	Clemmons DR	Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.	Nature reviews. Drug discovery	2007	90
18003755	3479	Hyppönen E	25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort.	Diabetes	2008	88
18591391	3479	Forouhi NG	Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000.	Diabetes	2008	134
18769445	3479	Cohen E	The insulin paradox: aging, proteotoxicity and neurodegeneration.	Nature reviews. Neuroscience	2008	88
19620249	3479	Vigneri P	Diabetes and cancer.	Endocrine-related cancer	2009	187
20345478	3479	Tsugane S	Insulin resistance and cancer: epidemiological evidence.	Cancer science	2010	42
20392809	3479	Smith TJ	Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?	Pharmacological reviews	2010	44
20663687	3479	Gallagher EJ	The proliferating role of insulin and insulin-like growth factors in cancer.	Trends in endocrinology and metabolism	2010	60
21195217	3479	Bredella MA	Determinants of bone mineral density in obese premenopausal women.	Bone	2011	40
21540285	3479	Gallagher EJ	Minireview: IGF, Insulin, and Cancer.	Endocrinology	2011	83
21741057	3479	Sienkiewicz E	Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.	Metabolism	2011	41
22476197	3479	Talbot K	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.	The Journal of clinical investigation	2012	235
22701472	3479	Arcidiacono B	Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.	Experimental diabetes research	2012	64
22840388	3479	Fine EJ	Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients.	Nutrition	2012	32
23620761	3479	Sarfstein R	Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.	PloS one	2013	28
26437621	3479	Baron J	Short and tall stature: a new paradigm emerges.	Nature reviews. Endocrinology	2015	16
26733412	3479	Aguirre GA	Insulin-like growth factor-1 deficiency and metabolic syndrome.	Journal of translational medicine	2016	15
12235117	3553	Maedler K	Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.	The Journal of clinical investigation	2002	229
12606524	3553	Spranger J	Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.	Diabetes	2003	249
14581396	3553	Mazurek T	Human epicardial adipose tissue is a source of inflammatory mediators.	Circulation	2003	266
15855327	3553	Brusko TM	Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes.	Diabetes	2005	83
16284605	3553	Demircan N	Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy.	Eye	2006	76
16387690	3553	Ahn KS	Transcription factor NF-kappaB: a sensor for smoke and stress signals.	Annals of the New York Academy of Sciences	2005	81
18664535	3553	Böni-Schnetzler M	Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.	The Journal of clinical endocrinology and metabolism	2008	58
19542207	3553	Larsen CM	Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.	Diabetes care	2009	87
19692116	3553	Richette P	Gout.	Lancet	2010	95
20588114	3553	Dinarello CA	Role of IL-1beta in type 2 diabetes.	Current opinion in endocrinology, diabetes, and obesity	2010	74
21297467	3553	Boden G	Obesity, insulin resistance and free fatty acids.	Current opinion in endocrinology, diabetes, and obesity	2011	127
21762124	3553	Menu P	The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.	Clinical and experimental immunology	2011	61
22412385	3553	Eizirik DL	The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines.	PLoS genetics	2012	82
22699287	3553	Cavelti-Weder C	Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.	Diabetes care	2012	49
23557933	3553	Tomé-Carneiro J	One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease.	Pharmacological research	2013	38
24520123	3553	Dalmas E	T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes.	Diabetes	2014	30
9389420	3569	Pickup JC	NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.	Diabetologia	1997	150
11287357	3569	Kern PA	Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.	American journal of physiology. Endocrinology and metabolism	2001	280
11303144	3569	Bruunsgaard H	Aging and proinflammatory cytokines.	Current opinion in hematology	2001	131
11445664	3569	Vozarova B	Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion.	Obesity research	2001	86
11994345	3569	Bastard JP	Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro.	The Journal of clinical endocrinology and metabolism	2002	90
12220549	3569	Ishihara K	IL-6 in autoimmune disease and chronic inflammatory proliferative disease.	Cytokine and growth factor reviews	2002	126
12379575	3569	Esposito K	Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress.	Circulation	2002	268
12637131	3569	Cohen HJ	Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly.	The American journal of medicine	2003	78
12840146	3569	Kiecolt-Glaser JK	Chronic stress and age-related increases in the proinflammatory cytokine IL-6.	Proceedings of the National Academy of Sciences of the United States of America	2003	248
14960743	3569	Petersen KF	Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes.	The New England journal of medicine	2004	463
15893251	3569	Vgontzas AN	Sleep apnea is a manifestation of the metabolic syndrome.	Sleep medicine reviews	2005	68
16046295	3569	Di Gregorio GB	Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.	Diabetes	2005	111
16227461	3569	Punjabi NM	Disorders of glucose metabolism in sleep apnea.	Journal of applied physiology	2005	84
16412224	3569	Baker AR	Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease.	Cardiovascular diabetology	2006	121
16563942	3569	Petersen KF	Etiology of insulin resistance.	The American journal of medicine	2006	169
16613757	3569	Bastard JP	Recent advances in the relationship between obesity, inflammation, and insulin resistance.	European cytokine network	2006	383
16737350	3569	Yang RZ	Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications.	PLoS medicine	2006	69
17003332	3569	Carey AL	Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase.	Diabetes	2006	134
17090751	3569	Creely SJ	Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes.	American journal of physiology. Endocrinology and metabolism	2007	160
17114290	3569	Petersen KF	Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men.	Proceedings of the National Academy of Sciences of the United States of America	2006	82
17170049	3569	de Jager W	Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.	Annals of the rheumatic diseases	2007	62
17287468	3569	Fontana L	Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.	Diabetes	2007	203
17654441	3569	Hartge MM	The endothelium and vascular inflammation in diabetes.	Diabetes and vascular disease research	2007	55
18220642	3569	Hamdy O	Metabolic obesity: the paradox between visceral and subcutaneous fat.	Current diabetes reviews	2006	96
18633101	3569	Reyna SM	Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects.	Diabetes	2008	90
18689695	3569	Balkau B	Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR).	Diabetes care	2008	55
18776137	3569	Miao F	Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes.	Diabetes	2008	53
18926322	3569	Martin SS	Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease.	Journal of the American College of Cardiology	2008	92
19139294	3569	Sonnen JA	Different patterns of cerebral injury in dementia with or without diabetes.	Archives of neurology	2009	60
19259271	3569	Klöting N	MicroRNA expression in human omental and subcutaneous adipose tissue.	PloS one	2009	69
19460915	3569	Catalano PM	Fetuses of obese mothers develop insulin resistance in utero.	Diabetes care	2009	132
19794059	3569	Mehta NN	Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.	Diabetes	2010	82
19997642	3569	Yoshimura T	Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases.	PloS one	2009	67
20664016	3569	Brown TT	Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.	Diabetes care	2010	60
21358855	3569	Schmid SM	Disturbed glucoregulatory response to food intake after moderate sleep restriction.	Sleep	2011	41
21377916	3569	Neurath MF	IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.	Cytokine and growth factor reviews	2011	102
21964948	3569	Zeng C	The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications.	Journal of molecular medicine	2012	36
22035595	3569	Mirza S	Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study.	Cytokine	2012	35
22146091	3569	Pervanidou P	Metabolic consequences of stress during childhood and adolescence.	Metabolism	2012	45
22421340	3569	Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.	Lancet	2012	130
23034965	3569	Itariu BK	Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial.	The American journal of clinical nutrition	2012	38
23340215	3569	Singh AK	Metabolic syndrome and chronic kidney disease.	Current opinion in nephrology and hypertension	2013	27
23390498	3569	Panchapakesan U	Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?	PloS one	2013	29
23407306	3569	Belenchia AM	Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial.	The American journal of clinical nutrition	2013	46
23482247	3569	Basaranoglu M	Fructose as a key player in the development of fatty liver disease.	World journal of gastroenterology	2013	44
24370923	3569	Daniele G	The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus.	Acta diabetologica	2014	21
24622416	3569	Gitelman SE	Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.	The lancet. Diabetes and endocrinology	2013	29
24751614	3569	Pal M	From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation.	Immunology and cell biology	2014	30
25787249	3569	Puthanveetil P	Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells.	Journal of cellular and molecular medicine	2015	18
25849830	3569	Couturier J	Human adipose tissue as a reservoir for memory CD4+ T cells and HIV.	AIDS	2015	16
26781070	3569	Domingueti CP	Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications.	Journal of diabetes and its complications	2016	18
1357346	3630	Martin BC	Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.	Lancet	1992	138
1551497	3630	Van Cauter E	Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance.	Diabetes	1992	148
1671422	3630	McKeigue PM	Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians.	Lancet	1991	260
1954451	3630	Hales CN	Fetal and infant growth and impaired glucose tolerance at age 64.	BMJ	1991	360
2044434	3630	DeFronzo RA	Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.	Diabetes care	1991	373
2403659	3630	Shulman GI	Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy.	The New England journal of medicine	1990	193
3056758	3630	Reaven GM	Banting lecture 1988. Role of insulin resistance in human disease.	Diabetes	1988	1192
3288530	3630	Ricordi C	Automated method for isolation of human pancreatic islets.	Diabetes	1988	205
3514343	3630	Nauck M	Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.	Diabetologia	1986	177
3899825	3630	Matthews DR	Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.	Diabetologia	1985	4427
6367725	3630	Klein R	The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.	Archives of ophthalmology	1984	199
7624391	3630	Reaven GM	Pathophysiology of insulin resistance in human disease.	Physiological reviews	1995	131
7677463	3630	Pories WJ	Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.	Annals of surgery	1995	248
7738205	3630	Hotamisligil GS	Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.	The Journal of clinical investigation	1995	471
7839388	3630	Sacco RL	Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.	Stroke	1995	138
7935656	3630	Nolan JJ	Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.	The New England journal of medicine	1994	126
8247074	3630	Lillioja S	Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians.	The New England journal of medicine	1993	204
8436255	3630	Barker DJ	Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth.	Diabetologia	1993	325
8447318	3630	Spielman RS	Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM).	American journal of human genetics	1993	715
8627431	3630	Pinhas-Hamiel O	Increased incidence of non-insulin-dependent diabetes mellitus among adolescents.	The Journal of pediatrics	1996	115
8857019	3630	Perseghin G	Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects.	The New England journal of medicine	1996	114
9042129	3630	Anderson B	Parental involvement in diabetes management tasks: relationships to blood glucose monitoring adherence and metabolic control in young adolescents with insulin-dependent diabetes mellitus.	The Journal of pediatrics	1997	108
9054944	3630	Vafiadis P	Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus.	Nature genetics	1997	137
9281381	3630	Jacobson DL	Epidemiology and estimated population burden of selected autoimmune diseases in the United States.	Clinical immunology and immunopathology	1997	226
9303923	3630	Ferrannini E	Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).	The Journal of clinical investigation	1997	116
9449872	3630	Ravelli AC	Glucose tolerance in adults after prenatal exposure to famine.	Lancet	1998	210
9450510	3630	Amos AF	The rising global burden of diabetes and its complications: estimates and projections to the year 2010.	Diabetic medicine 	1997	207
9509261	3630	Goodyear LJ	Exercise, glucose transport, and insulin sensitivity.	Annual review of medicine	1998	149
9593791	3630	Redelmeier DA	The treatment of unrelated disorders in patients with chronic medical diseases.	The New England journal of medicine	1998	130
9619798	3630	Carr A	A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.	AIDS	1998	266
9673301	3630	Haffner SM	Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.	The New England journal of medicine	1998	841
9710447	3630	Barber AJ	Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.	The Journal of clinical investigation	1998	263
9920074	3630	Banerji MA	Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men.	The Journal of clinical endocrinology and metabolism	1999	100
10189543	3630	-	The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.	Diabetes care	1999	180
10382692	3630	Carr A	Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.	Lancet	1999	169
10454950	3630	DeFronzo RA	Pharmacologic therapy for type 2 diabetes mellitus.	Annals of internal medicine	1999	109
10512371	3630	Moran A	Insulin resistance during puberty: results from clamp studies in 357 children.	Diabetes	1999	131
10550418	3630	Meyer TW	Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria.	Diabetologia	1999	104
10645822	3630	Hanson RL	Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies.	American journal of epidemiology	2000	97
10731493	3630	Goodpaster BH	Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus.	The American journal of clinical nutrition	2000	140
10731498	3630	Meyer KA	Carbohydrates, dietary fiber, and incident type 2 diabetes in older women.	The American journal of clinical nutrition	2000	148
10788730	3630	Block G	A rapid food screener to assess fat and fruit and vegetable intake.	American journal of preventive medicine	2000	102
10857969	3630	Bonora E	Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.	Diabetes care	2000	347
10868930	3630	Soria B	Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice.	Diabetes	2000	111
10902785	3630	Katz A	Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.	The Journal of clinical endocrinology and metabolism	2000	472
10911004	3630	Shapiro AM	Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.	The New England journal of medicine	2000	729
11270671	3630	Stratton IM	UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.	Diabetologia	2001	140
11274526	3630	Visscher TL	The public health impact of obesity.	Annual review of public health	2001	128
11289033	3630	Ryan EA	Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.	Diabetes	2001	90
11533341	3630	Freedman DS	Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study.	Pediatrics	2001	213
11587045	3630	Morrish NJ	Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.	Diabetologia	2001	167
11794168	3630	van den Berghe G	Intensive insulin therapy in critically ill patients.	The New England journal of medicine	2001	1145
11809615	3630	Hales CN	The thrifty phenotype hypothesis.	British medical bulletin	2001	378
11812755	3630	Vozarova B	High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes.	Diabetes	2002	84
11861436	3630	Sacks DB	Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.	Clinical chemistry	2002	122
11872682	3630	Mayerson AB	The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.	Diabetes	2002	98
11874813	3630	Punjabi NM	Sleep-disordered breathing and insulin resistance in middle-aged and overweight men.	American journal of respiratory and critical care medicine	2002	161
11893791	3630	Sinha R	Prevalence of impaired glucose tolerance among children and adolescents with marked obesity.	The New England journal of medicine	2002	208
12037147	3630	Diabetes Prevention Trial--Type 1 Diabetes Study Group.	Effects of insulin in relatives of patients with type 1 diabetes mellitus.	The New England journal of medicine	2002	136
12081851	3630	Willett W	Glycemic index, glycemic load, and risk of type 2 diabetes.	The American journal of clinical nutrition	2002	81
12086926	3630	Itani SI	Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha.	Diabetes	2002	277
12087016	3630	Hanley AJ	Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.	Diabetes care	2002	96
12136392	3630	Cryer PE	Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.	Diabetologia	2002	160
12174319	3630	Korytkowski M	When oral agents fail: practical barriers to starting insulin.	International journal of obesity and related metabolic disorders 	2002	100
12196473	3630	Buchanan TA	Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.	Diabetes	2002	184
12364302	3630	DAFNE Study Group.	Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial.	BMJ	2002	123
12364344	3630	Sorof J	Obesity hypertension in children: a problem of epidemic proportions.	Hypertension	2002	97
12367816	3630	Barker DJ	Fetal programming of coronary heart disease.	Trends in endocrinology and metabolism	2002	122
12490658	3630	Pi-Sunyer FX	The obesity epidemic: pathophysiology and consequences of obesity.	Obesity research	2002	105
12540621	3630	Garvey WT	Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.	Diabetes	2003	93
12551870	3630	Rutter MK	Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study.	Circulation	2003	97
12562574	3630	Ryan MC	Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.	The American journal of psychiatry	2003	104
12576937	3630	Van den Berghe G	Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control.	Critical care medicine	2003	108
12606496	3630	Robertson RP	Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection.	Diabetes	2003	124
12610045	3630	Steffes MW	Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.	Diabetes care	2003	135
12642369	3630	Steinberger J	Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism).	Circulation	2003	121
12668987	3630	Marchesini G	Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.	Hepatology	2003	435
12679416	3630	Goran MI	Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents.	The Journal of clinical endocrinology and metabolism	2003	100
12717402	3630	Neuschwander-Tetri BA	Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.	Hepatology	2003	351
12750520	3630	Petersen KF	Mitochondrial dysfunction in the elderly: possible role in insulin resistance.	Science	2003	450
12766131	3630	Cryer PE	Hypoglycemia in diabetes.	Diabetes care	2003	183
12771873	3630	Furnary AP	Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.	The Journal of thoracic and cardiovascular surgery	2003	119
12829641	3630	Basu R	Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance.	Diabetes	2003	84
14623617	3630	McLaughlin T	Use of metabolic markers to identify overweight individuals who are insulin resistant.	Annals of internal medicine	2003	151
14633821	3630	Ascaso JF	Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism.	Diabetes care	2003	82
14693724	3630	Palmer JP	C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.	Diabetes	2004	112
14704320	3630	Yajnik CS	Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries.	The Journal of nutrition	2004	81
14715836	3630	Cruz ML	The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity.	The Journal of clinical endocrinology and metabolism	2004	100
14752837	3630	Promrat K	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.	Hepatology	2004	112
14985484	3630	Bhargava SK	Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood.	The New England journal of medicine	2004	186
15111553	3630	Cramer JA	A systematic review of adherence with medications for diabetes.	Diabetes care	2004	223
15161770	3630	Heise T	Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.	Diabetes	2004	76
15292279	3630	Hull RL	Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes.	The Journal of clinical endocrinology and metabolism	2004	122
15477536	3630	Luchsinger JA	Hyperinsulinemia and risk of Alzheimer disease.	Neurology	2004	139
15480982	3630	Yang YX	Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.	Gastroenterology	2004	83
15548778	3630	Hofman PL	Premature birth and later insulin resistance.	The New England journal of medicine	2004	76
15564314	3630	Gershengorn MC	Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells.	Science	2004	100
15630069	3630	Henderson DC	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.	Archives of general psychiatry	2005	67
15639678	3630	Pereira MA	Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis.	Lancet	2005	228
15662003	3630	Rhodes CJ	Type 2 diabetes-a matter of beta-cell life and death?	Science	2005	195
15669880	3630	Krentz AJ	Oral antidiabetic agents: current role in type 2 diabetes mellitus.	Drugs	2005	126
15723702	3630	Basciano H	Fructose, insulin resistance, and metabolic dyslipidemia.	Nutrition and metabolism	2005	129
15734833	3630	Petersen KF	Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.	Diabetes	2005	183
15802102	3630	Shaffer EA	Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century?	Current gastroenterology reports	2005	70
15864529	3630	Kolb H	An immune origin of type 2 diabetes?	Diabetologia	2005	66
15883415	3630	Nair KS	Aging muscle.	The American journal of clinical nutrition	2005	82
15910627	3630	Donnelly LA	Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study.	Diabetic medicine 	2005	74
15946424	3630	Wickremesekera K	Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study.	Obesity surgery	2005	69
15951574	3630	Crowther CA	Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.	The New England journal of medicine	2005	333
15983207	3630	Ryan EA	Five-year follow-up after clinical islet transplantation.	Diabetes	2005	338
15998259	3630	Evans JL	The molecular basis for oxidative stress-induced insulin resistance.	Antioxidants and redox signaling	2005	85
16030278	3630	Ingelsson E	Insulin resistance and risk of congestive heart failure.	JAMA	2005	110
16046308	3630	Kitabchi AE	Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.	Diabetes	2005	130
16061606	3630	Hannon TS	Childhood obesity and type 2 diabetes mellitus.	Pediatrics	2005	67
16061755	3630	Dekker JM	Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.	Circulation	2005	91
16103522	3630	Bassuk SS	Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease.	Journal of applied physiology	2005	88
16105055	3630	Taylor EN	Diabetes mellitus and the risk of nephrolithiasis.	Kidney international	2005	83
16155268	3630	Robertson MD	Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism.	The American journal of clinical nutrition	2005	69
16186296	3630	Polonsky WH	Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.	Diabetes care	2005	90
16211373	3630	Dunstan DW	Associations of TV viewing and physical activity with the metabolic syndrome in Australian adults.	Diabetologia	2005	82
16230722	3630	Heine RJ	Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.	Annals of internal medicine	2005	142
16249538	3630	Peyrot M	Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.	Diabetes care	2005	148
16332653	3630	Albu JB	Independent association of insulin resistance with larger amounts of intermuscular adipose tissue and a greater acute insulin response to glucose in African American than in white nondiabetic women.	The American journal of clinical nutrition	2005	66
16352795	3630	Stolzenberg-Solomon RZ	Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.	JAMA	2005	104
16352960	3630	Kanji S	Reliability of point-of-care testing for glucose measurement in critically ill adults.	Critical care medicine	2005	86
16361024	3630	Biessels GJ	Risk of dementia in diabetes mellitus: a systematic review.	The Lancet. Neurology	2006	296
16388523	3630	Basaria S	Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.	Cancer	2006	65
16434464	3630	Smith MR	Insulin sensitivity during combined androgen blockade for prostate cancer.	The Journal of clinical endocrinology and metabolism	2006	98
16443778	3630	Ostenson CG	Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients.	Diabetes	2006	64
16443869	3630	Bowker SL	Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.	Diabetes care	2006	233
16456680	3630	Yki-Järvinen H	Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.	Diabetologia	2006	83
16532897	3630	Serra-Majem L	Scientific evidence of interventions using the Mediterranean diet: a systematic review.	Nutrition reviews	2006	73
16556766	3630	Wiederkehr A	Minireview: implication of mitochondria in insulin secretion and action.	Endocrinology	2006	69
16567536	3630	Festa A	The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study.	Diabetes	2006	73
16644702	3630	Clerk LH	Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle.	Diabetes	2006	80
16704347	3630	King JC	Maternal obesity, metabolism, and pregnancy outcomes.	Annual review of nutrition	2006	62
16773565	3630	Saxena R	Comprehensive association testing of common mitochondrial DNA variation in metabolic disease.	American journal of human genetics	2006	79
16801565	3630	Knopp RH	Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).	Diabetes care	2006	69
16824015	3630	Heit JJ	Intrinsic regulators of pancreatic beta-cell proliferation.	Annual review of cell and developmental biology	2006	76
16873706	3630	Draznin B	Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin.	Diabetes	2006	70
17021763	3630	Sommer DM	Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.	Archives of dermatological research	2006	84
17065355	3630	Van den Berghe G	Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm.	Diabetes	2006	73
17065679	3630	Lee JM	Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study.	Diabetes care	2006	99
17145742	3630	Kahn SE	Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.	The New England journal of medicine	2006	516
17261637	3630	Gromada J	Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.	Endocrine reviews	2007	149
17339025	3630	Holland WL	Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.	Cell metabolism	2007	313
17344486	3630	Corcoran MP	Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise.	The American journal of clinical nutrition	2007	57
17443605	3630	Horvath K	Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.	The Cochrane database of systematic reviews	2007	62
17666486	3630	Bertram R	Metabolic and electrical oscillations: partners in controlling pulsatile insulin secretion.	American journal of physiology. Endocrinology and metabolism	2007	69
17707755	3630	Messerli FH	Essential hypertension.	Lancet	2007	76
17728149	3630	Adams LA	Nonalcoholic fatty liver disease.	Annals of epidemiology	2007	66
17875176	3630	Ferrante AW Jr	Obesity-induced inflammation: a metabolic dialogue in the language of inflammation.	Journal of internal medicine	2007	111
17926672	3630	Dalla Man C	Meal simulation model of the glucose-insulin system.	IEEE transactions on bio-medical engineering	2007	82
17957034	3630	Muniyappa R	Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.	American journal of physiology. Endocrinology and metabolism	2008	261
17981116	3630	Pospisilik JA	Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes.	Cell	2007	143
18070991	3630	Sardinha LB	Objectively measured time spent sedentary is associated with insulin resistance independent of overall and central body fat in 9- to 10-year-old Portuguese children.	Diabetes care	2008	58
18158075	3630	Barnett AH	Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.	Clinical therapeutics	2007	62
18162506	3630	Edghill EL	Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.	Diabetes	2008	80
18192540	3630	Molven A	Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes.	Diabetes	2008	50
18250214	3630	Tasali E	Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation.	Proceedings of the American Thoracic Society	2008	75
18265476	3630	Xue F	Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence.	The American journal of clinical nutrition	2007	92
18285809	3630	Farrant HJ	Vitamin D insufficiency is common in Indian mothers but is not associated with gestational diabetes or variation in newborn size.	European journal of clinical nutrition	2009	48
18288110	3630	Kroon E	Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo.	Nature biotechnology	2008	489
18312311	3630	James WP	The epidemiology of obesity: the size of the problem.	Journal of internal medicine	2008	137
18319314	3630	Grossmann M	Low testosterone levels are common and associated with insulin resistance in men with diabetes.	The Journal of clinical endocrinology and metabolism	2008	63
18347614	3630	Lawrence MC	The roles of MAPKs in disease.	Cell research	2008	54
18374840	3630	Bretzel RG	Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.	Lancet	2008	69
18401346	3630	Guilherme A	Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.	Nature reviews. Molecular cell biology	2008	417
18436705	3630	Scheuner D	The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes.	Endocrine reviews	2008	153
18451997	3630	Colombo C	Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus.	The Journal of clinical investigation	2008	60
18463376	3630	Rowan JA	Metformin versus insulin for the treatment of gestational diabetes.	The New England journal of medicine	2008	103
18474251	3630	Kotronen A	Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.	Gastroenterology	2008	52
18544448	3630	Shaw JE	Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention.	Diabetes research and clinical practice	2008	58
18673007	3630	King GL	The role of inflammatory cytokines in diabetes and its complications.	Journal of periodontology	2008	90
18682704	3630	Shaham O	Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity.	Molecular systems biology	2008	114
18796548	3630	Cacho J	Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats.	American journal of physiology. Endocrinology and metabolism	2008	78
18801863	3630	Cade WT	Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.	Physical therapy	2008	62
18802479	3630	Skowera A	CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.	The Journal of clinical investigation	2008	115
18834431	3630	Rahier J	Pancreatic beta-cell mass in European subjects with type 2 diabetes.	Diabetes, obesity and metabolism	2008	173
18854399	3630	Fernández-Real JM	The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training.	The Journal of clinical endocrinology and metabolism	2009	51
18987276	3630	Misra A	Obesity and the metabolic syndrome in developing countries.	The Journal of clinical endocrinology and metabolism	2008	182
19008343	3630	Haus JM	Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.	Diabetes	2009	104
19073504	3630	Goodwin PJ	Insulin-lowering effects of metformin in women with early breast cancer.	Clinical breast cancer	2008	53
19088155	3630	Cryer PE	Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.	The Journal of clinical endocrinology and metabolism	2009	102
19141606	3630	Maratou E	Studies of insulin resistance in patients with clinical and subclinical hypothyroidism.	European journal of endocrinology	2009	49
19196887	3630	Bunck MC	One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.	Diabetes care	2009	105
19202385	3630	Fedor D	Prevention of insulin resistance by n-3 polyunsaturated fatty acids.	Current opinion in clinical nutrition and metabolic care	2009	58
19246357	3630	Sacks FM	Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.	The New England journal of medicine	2009	293
19272486	3630	Buchwald H	Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.	The American journal of medicine	2009	340
19281826	3630	Roberts CK	Oxidative stress and metabolic syndrome.	Life sciences	2009	108
19332493	3630	Brøns C	Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men.	The Journal of physiology	2009	50
19358089	3630	Blüher M	Adipose tissue dysfunction in obesity.	Experimental and clinical endocrinology and diabetes 	2009	101
19365105	3630	Zeyda M	Obesity, inflammation, and insulin resistance--a mini-review.	Gerontology	2009	67
19375425	3630	Li D	Antidiabetic therapies affect risk of pancreatic cancer.	Gastroenterology	2009	163
19407331	3630	Huang PL	A comprehensive definition for metabolic syndrome.	Disease models and mechanisms	2009	93
19470610	3630	Helmerhorst HJ	Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity.	Diabetes	2009	65
19515410	3630	Tabák AG	Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.	Lancet	2009	150
19528367	3630	Wilding JP	A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.	Diabetes care	2009	80
19565214	3630	Hemkens LG	Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.	Diabetologia	2009	140
19588120	3630	Jonasson JM	Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.	Diabetologia	2009	97
19603149	3630	Colhoun HM	Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.	Diabetologia	2009	96
19742322	3630	Kuroda A	Insulin gene expression is regulated by DNA methylation.	PloS one	2009	61
19759171	3630	Catalano PM	Perinatal risk factors for childhood obesity and metabolic dysregulation.	The American journal of clinical nutrition	2009	100
19781131	3630	von Hurst PR	Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial.	The British journal of nutrition	2010	124
19789205	3630	Kalyani RR	The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women.	The Journal of clinical endocrinology and metabolism	2009	51
19793375	3630	Heneghan HM	Role of microRNAs in obesity and the metabolic syndrome.	Obesity reviews 	2010	50
19797280	3630	Landon MB	A multicenter, randomized trial of treatment for mild gestational diabetes.	The New England journal of medicine	2009	227
19833877	3630	Hwang H	Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes.	Diabetes	2010	57
19833891	3630	Coen PM	Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content.	Diabetes	2010	52
19859074	3630	Zitzmann M	Testosterone deficiency, insulin resistance and the metabolic syndrome.	Nature reviews. Endocrinology	2009	46
19915016	3630	Nadeau KJ	Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.	The Journal of clinical endocrinology and metabolism	2010	71
19958890	3630	Botros N	Obstructive sleep apnea as a risk factor for type 2 diabetes.	The American journal of medicine	2009	62
19966268	3630	Nelson SM	Maternal metabolism and obesity: modifiable determinants of pregnancy outcome.	Human reproduction update	2010	61
20007948	3630	Holzinger U	Real-time continuous glucose monitoring in critically ill patients: a prospective randomized trial.	Diabetes care	2010	48
20022465	3630	Das UN	Obesity: genes, brain, gut, and environment.	Nutrition	2010	45
20079586	3630	Wulan SN	Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians.	Maturitas	2010	40
20086073	3630	Tappy L	Metabolic effects of fructose and the worldwide increase in obesity.	Physiological reviews	2010	188
20086256	3630	Karter AJ	Barriers to insulin initiation: the translating research into action for diabetes insulin starts project.	Diabetes care	2010	45
20091571	3630	Misso ML	Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.	The Cochrane database of systematic reviews	2010	45
20103556	3630	Peyrot M	Correlates of insulin injection omission.	Diabetes care	2010	77
20171982	3630	Lambert GW	Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.	Pharmacology and therapeutics	2010	72
20181961	3630	Bhandare R	Genome-wide analysis of histone modifications in human pancreatic islets.	Genome research	2010	53
20185812	3630	Yang X	Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.	Diabetes	2010	40
20220183	3630	Patel MR	Low diagnostic yield of elective coronary angiography.	The New England journal of medicine	2010	132
20228402	3630	NAVIGATOR Study Group.	Effect of nateglinide on the incidence of diabetes and cardiovascular events.	The New England journal of medicine	2010	73
20339361	3630	Preis SR	Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study.	Obesity	2010	80
20353613	3630	Gallagher IJ	Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes.	Genome medicine	2010	60
20357360	3630	Wentworth JM	Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity.	Diabetes	2010	106
20361178	3630	DeFronzo RA	Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.	Diabetologia	2010	131
20370677	3630	Bugianesi E	Insulin resistance in nonalcoholic fatty liver disease.	Current pharmaceutical design	2010	50
20376052	3630	Hotamisligil GS	Endoplasmic reticulum stress and atherosclerosis.	Nature medicine	2010	70
20442309	3630	Ben Sahra I	Metformin in cancer therapy: a new perspective for an old antidiabetic drug?	Molecular cancer therapeutics	2010	133
20457594	3630	Catalano PM	Obesity, insulin resistance, and pregnancy outcome.	Reproduction	2010	50
20480025	3630	Hanhineva K	Impact of dietary polyphenols on carbohydrate metabolism.	International journal of molecular sciences	2010	69
20522594	3630	Kars M	Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women.	Diabetes	2010	93
20581420	3630	HEALTHY Study Group.	A school-based intervention for diabetes risk reduction.	The New England journal of medicine	2010	86
20724178	3630	Liu M	Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth.	Trends in endocrinology and metabolism	2010	43
20798346	3630	Unger RH	Paracrinology of islets and the paracrinopathy of diabetes.	Proceedings of the National Academy of Sciences of the United States of America	2010	67
20829185	3630	Levy-Marchal C	Insulin resistance in children: consensus, perspective, and future directions.	The Journal of clinical endocrinology and metabolism	2010	50
20978091	3630	Schauer IE	Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study.	Diabetes	2011	48
21045171	3630	LeBrasseur NK	Metabolic benefits of resistance training and fast glycolytic skeletal muscle.	American journal of physiology. Endocrinology and metabolism	2011	36
21051417	3630	Yu Q	Insulin says NO to cardiovascular disease.	Cardiovascular research	2011	36
21070248	3630	Belgardt BF	CNS leptin and insulin action in the control of energy homeostasis.	Annals of the New York Academy of Sciences	2010	67
21104225	3630	Yang BT	Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets.	Diabetologia	2011	47
21128002	3630	Nguyen NT	Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006.	Obesity surgery	2011	52
21159388	3630	Tiganis T	Reactive oxygen species and insulin resistance: the good, the bad and the ugly.	Trends in pharmacological sciences	2011	44
21170321	3630	Fiehn O	Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women.	PloS one	2010	83
21216854	3630	Schmid AI	Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.	Diabetes care	2011	36
21245030	3630	Hooper AJ	Genetic determinants of hepatic steatosis in man.	Journal of lipid research	2011	42
21270174	3630	Birkeland KI	Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.	Diabetes care	2011	40
21288502	3630	Catalano PM	Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic?	American journal of obstetrics and gynecology	2011	63
21298090	3630	Lee DH	Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes.	PloS one	2011	78
21321035	3630	Seifert SM	Health effects of energy drinks on children, adolescents, and young adults.	Pediatrics	2011	100
21350183	3630	Chiang DJ	Obesity, diabetes mellitus, and liver fibrosis.	American journal of physiology. Gastrointestinal and liver physiology	2011	39
21362568	3630	Smukler SR	The adult mouse and human pancreas contain rare multipotent stem cells that express insulin.	Cell stem cell	2011	58
21367930	3630	Steil GM	The effect of insulin feedback on closed loop glucose control.	The Journal of clinical endocrinology and metabolism	2011	49
21403394	3630	Rhee EP	Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans.	The Journal of clinical investigation	2011	117
21466619	3630	Long AN	Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection.	Journal of clinical hypertension	2011	39
21471135	3630	Schramm TK	Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.	European heart journal	2011	63
21536711	3630	Semple RK	Genetic syndromes of severe insulin resistance.	Endocrine reviews	2011	40
21562325	3630	Steck AK	Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young.	Diabetes care	2011	56
21593290	3630	Katula JA	One-year results of a community-based translation of the Diabetes Prevention Program: Healthy-Living Partnerships to Prevent Diabetes (HELP PD) Project.	Diabetes care	2011	59
21599535	3630	Leavens KF	Insulin signaling to hepatic lipid metabolism in health and disease.	Critical reviews in biochemistry and molecular biology	2011	37
21614570	3630	Camastra S	Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes.	Diabetologia	2011	37
21617108	3630	Sacks DB	Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.	Diabetes care	2011	65
21617152	3630	Sacks DB	Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.	Clinical chemistry	2011	56
21632448	3630	La Vecchia C	Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle.	The oncologist	2011	39
21709297	3630	Uribarri J	Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1.	Diabetes care	2011	51
21718726	3630	Dongiovanni P	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target.	Journal of hepatology	2011	59
21719444	3630	Musselman LP	A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila.	Disease models and mechanisms	2011	86
21730284	3630	Giannini C	The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds.	Diabetes care	2011	41
21762726	3630	Poudyal H	Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action.	Progress in lipid research	2011	42
21778224	3630	Srikanthan P	Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey.	The Journal of clinical endocrinology and metabolism	2011	99
21864748	3630	Henquin JC	The dual control of insulin secretion by glucose involves triggering and amplifying pathways in β-cells.	Diabetes research and clinical practice	2011	42
21865645	3630	Ravassard P	A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion.	The Journal of clinical investigation	2011	72
21873552	3630	Amati F	Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes?	Diabetes	2011	93
21912398	3630	Szendroedi J	The role of mitochondria in insulin resistance and type 2 diabetes mellitus.	Nature reviews. Endocrinology	2011	92
21930939	3630	Kumashiro N	Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease.	Proceedings of the National Academy of Sciences of the United States of America	2011	104
21956710	3630	Ruiter R	Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.	Diabetologia	2012	38
22124462	3630	Yu L	Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay.	Diabetes	2012	32
22162232	3630	Li D	Diabetes and pancreatic cancer.	Molecular carcinogenesis	2012	53
22167125	3630	Dai C	Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets.	Diabetologia	2012	53
22167127	3630	Cooper AR	Sedentary time, breaks in sedentary time and metabolic variables in people with newly diagnosed type 2 diabetes.	Diabetologia	2012	36
22194737	3630	Mazza A	The role of metformin in the management of NAFLD.	Experimental diabetes research	2012	32
22245737	3630	Bulek AM	Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.	Nature immunology	2012	48
22278418	3630	Chen G	Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.	The Journal of clinical endocrinology and metabolism	2012	33
22313123	3630	Peyrot M	Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study.	Diabetic medicine 	2012	74
22326434	3630	Cusi K	Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.	Gastroenterology	2012	112
22332072	3630	Kalupahana NS	(n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights.	Advances in nutrition	2011	49
22344039	3630	Fraser A	Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children.	Circulation	2012	52
22350783	3630	Deng L	Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis.	Digestive diseases and sciences	2012	33
22352879	3630	King AJ	The use of animal models in diabetes research.	British journal of pharmacology	2012	98
22355097	3630	Dowling RJ	Metformin in cancer: translational challenges.	Journal of molecular endocrinology	2012	75
22431673	3630	Wilding JP	Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.	Annals of internal medicine	2012	81
22486204	3630	George PS	Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis.	Diabetic medicine 	2012	56
22494609	3630	Bellin MD	Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes.	American journal of transplantation 	2012	64
22496545	3630	Buxton OM	Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption.	Science translational medicine	2012	138
22500228	3630	Duarte AI	Insulin in central nervous system: more than just a peripheral hormone.	Journal of aging research	2012	44
22521071	3630	Heller S	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.	Lancet	2012	72
22521072	3630	Garber AJ	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.	Lancet	2012	70
22560210	3630	Jornayvaz FR	Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance.	Cell metabolism	2012	65
22592687	3630	Tang T	Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.	The Cochrane database of systematic reviews	2012	47
22718433	3630	Friedrich N	Metabolomics in diabetes research.	The Journal of endocrinology	2012	33
22719752	3630	Hsieh MC	The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese.	Experimental diabetes research	2012	39
22740171	3630	Rezania A	Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice.	Diabetes	2012	98
22741595	3630	Liu CJ	Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.	Journal of gastroenterology and hepatology	2012	34
22745242	3630	Gregg BE	Formation of a human β-cell population within pancreatic islets is set early in life.	The Journal of clinical endocrinology and metabolism	2012	76
22751341	3630	Buchanan TA	Gestational diabetes mellitus: risks and management during and after pregnancy.	Nature reviews. Endocrinology	2012	32
22777524	3630	Yeh HC	Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.	Annals of internal medicine	2012	48
22827862	3630	Lucassen EA	Interacting epidemics? Sleep curtailment, insulin resistance, and obesity.	Annals of the New York Academy of Sciences	2012	37
22847239	3630	Sell H	Adaptive immunity in obesity and insulin resistance.	Nature reviews. Endocrinology	2012	72
22876189	3630	Voight BF	The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits.	PLoS genetics	2012	190
22926251	3630	Pollak MN	Investigating metformin for cancer prevention and treatment: the end of the beginning.	Cancer discovery	2012	118
22974438	3630	Rorsman P	Regulation of insulin secretion in human pancreatic islets.	Annual review of physiology	2013	74
23043166	3630	Zinman B	Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).	Diabetes care	2012	62
23065822	3630	Diamanti-Kandarakis E	Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.	Endocrine reviews	2012	110
23069842	3630	Willette AA	Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults.	Diabetes care	2013	37
23086558	3630	Herold KC	Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.	Diabetologia	2013	28
23099275	3630	Kwon KC	Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.	Advanced drug delivery reviews	2013	35
23129134	3630	Würtz P	Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults.	Diabetes care	2013	65
23161525	3630	Arterburn DE	A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass.	Obesity surgery	2013	55
23169676	3630	Girgis CM	The roles of vitamin D in skeletal muscle: form, function, and metabolism.	Endocrine reviews	2013	55
23223406	3630	Pisprasert V	Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans.	Diabetes care	2013	28
23269411	3630	Ye J	Inflammation during obesity is not all bad: evidence from animal and human studies.	American journal of physiology. Endocrinology and metabolism	2013	27
23274890	3630	Gao H	Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study.	Diabetes	2013	25
23302862	3630	Menting JG	How insulin engages its primary binding site on the insulin receptor.	Nature	2013	57
23315061	3630	Stepto NK	Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.	Human reproduction	2013	55
23359039	3630	Haidar A	Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.	CMAJ 	2013	34
23363012	3630	Masuoka HC	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.	Annals of the New York Academy of Sciences	2013	44
23368510	3630	Kapitza C	Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.	Diabetes, obesity and metabolism	2013	31
23370525	3630	Goldfine AB	A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance.	Diabetologia	2013	31
23381014	3630	Singh S	Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.	The American journal of gastroenterology	2013	48
23393185	3630	Mathieu C	Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.	The Journal of clinical endocrinology and metabolism	2013	38
23413806	3630	Jones AG	The clinical utility of C-peptide measurement in the care of patients with diabetes.	Diabetic medicine 	2013	38
23458891	3630	Farrell GC	NAFLD in Asia--as common and important as in the West.	Nature reviews. Gastroenterology and hepatology	2013	69
23485579	3630	De Felice FG	Alzheimer's disease and insulin resistance: translating basic science into clinical applications.	The Journal of clinical investigation	2013	41
23524641	3630	Butler AE	Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.	Diabetes	2013	90
23528347	3630	Sah RP	New insights into pancreatic cancer-induced paraneoplastic diabetes.	Nature reviews. Gastroenterology and hepatology	2013	40
23587769	3630	Groop L	Genetics of diabetes--are we missing the genes or the disease?	Molecular and cellular endocrinology	2014	28
23638642	3630	Gu Z	Injectable nano-network for glucose-mediated insulin delivery.	ACS nano	2013	27
23703888	3630	Lazo M	Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.	American journal of epidemiology	2013	112
23764390	3630	Croze ML	Potential role and therapeutic interests of myo-inositol in metabolic diseases.	Biochimie	2013	27
23778747	3630	Ho M	Impact of dietary and exercise interventions on weight change and metabolic outcomes in obese children and adolescents: a systematic review and meta-analysis of randomized trials.	JAMA pediatrics	2013	37
23796113	3630	Östenson CG	Self-reported non-severe hypoglycaemic events in Europe.	Diabetic medicine 	2014	21
23847240	3630	Wolpin BM	Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer.	Journal of the National Cancer Institute	2013	30
23850509	3630	Chen Z	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.	Progress in neurobiology	2013	53
23863634	3630	Ruderman NB	AMPK, insulin resistance, and the metabolic syndrome.	The Journal of clinical investigation	2013	120
23863826	3630	Misra A	Obesity and dyslipidemia in South Asians.	Nutrients	2013	32
23877060	3630	Cahill LE	Prospective study of breakfast eating and incident coronary heart disease in a cohort of male US health professionals.	Circulation	2013	29
23897112	3630	Thambisetty M	Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging.	JAMA neurology	2013	31
23916992	3630	Scharp DW	Encapsulated islets for diabetes therapy: history, current progress, and critical issues requiring solution.	Advanced drug delivery reviews	2014	26
23929732	3630	Birkenfeld AL	Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.	Hepatology	2014	70
23938049	3630	Bahadoran Z	Dietary polyphenols as potential nutraceuticals in management of diabetes: a review.	Journal of diabetes and metabolic disorders	2013	34
23994581	3630	Rettberg JR	Estrogen: a master regulator of bioenergetic systems in the brain and body.	Frontiers in neuroendocrinology	2014	33
24042324	3630	Ashcroft FM	K(ATP) channels and islet hormone secretion: new insights and controversies.	Nature reviews. Endocrinology	2013	41
24172179	3630	Scherer J	Issues in hypertriglyceridemic pancreatitis: an update.	Journal of clinical gastroenterology	2014	27
24215793	3630	Mezza T	Insulin resistance alters islet morphology in nondiabetic humans.	Diabetes	2014	27
24241533	3630	Bojsen-Møller KN	Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass.	Diabetes	2014	25
24250251	3630	Rajendran P	The vascular endothelium and human diseases.	International journal of biological sciences	2013	62
24252877	3630	Lee J	Expansion and conversion of human pancreatic ductal cells into insulin-secreting endocrine cells.	eLife	2013	33
24323910	3630	Turner N	Fatty acid metabolism, energy expenditure and insulin resistance in muscle.	The Journal of endocrinology	2014	24
24429158	3630	Aurora RN	Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association.	The Lancet. Respiratory medicine	2013	28
24458353	3630	Leproult R	Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss.	Diabetes	2014	68
24463448	3630	Merovci A	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.	The Journal of clinical investigation	2014	93
24519298	3630	Wang G	Preterm birth and random plasma insulin levels at birth and in early childhood.	JAMA	2014	23
24529130	3630	Alexopoulos N	Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis.	Atherosclerosis	2014	31
24626293	3630	Mo R	Emerging micro- and nanotechnology based synthetic approaches for insulin delivery.	Chemical Society reviews	2014	24
24628249	3630	Reutrakul S	Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes.	Annals of the New York Academy of Sciences	2014	33
24651807	3630	Cobelli C	The oral minimal model method.	Diabetes	2014	24
24663220	3630	Kim KH	Autophagy--a key player in cellular and body metabolism.	Nature reviews. Endocrinology	2014	47
24663222	3630	Laakso M	Insulin resistance and hyperglycaemia in cardiovascular disease development.	Nature reviews. Endocrinology	2014	31
24757202	3630	Chow E	Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.	Diabetes	2014	33
24899308	3630	Perry RJ	The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.	Nature	2014	100
24928681	3630	Montaigne D	Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients.	Circulation	2014	28
24931033	3630	De Felice FG	Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease.	Diabetes	2014	48
24931035	3630	Yarchoan M	Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.	Diabetes	2014	24
25002497	3630	Davies SK	Effect of sleep deprivation on the human metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2014	46
25028522	3630	Heni M	Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men.	Diabetes	2014	23
25056438	3630	Chondronikola M	Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans.	Diabetes	2014	93
25114296	3630	Buse JB	Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).	Diabetes care	2014	27
25176147	3630	Khan MT	Microbial modulation of insulin sensitivity.	Cell metabolism	2014	22
25211370	3630	Rezania A	Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells.	Nature biotechnology	2014	126
25261534	3630	Ferdinandy P	Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning.	Pharmacological reviews	2014	64
25287289	3630	Frier BM	Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications.	Nature reviews. Endocrinology	2014	28
25303484	3630	Chen X	Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance.	The Journal of clinical endocrinology and metabolism	2015	26
25348128	3630	Leproult R	Beneficial impact of sleep extension on fasting insulin sensitivity in adults with habitual sleep restriction.	Sleep	2015	16
25385852	3630	Montgomery MK	Mitochondrial dysfunction and insulin resistance: an update.	Endocrine connections	2015	25
25423564	3630	Palmer ND	Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study.	The Journal of clinical endocrinology and metabolism	2015	18
25642774	3630	Herold KC	β cell death and dysfunction during type 1 diabetes development in at-risk individuals.	The Journal of clinical investigation	2015	30
25703677	3630	Gustafson B	Insulin resistance and impaired adipogenesis.	Trends in endocrinology and metabolism	2015	34
25754552	3630	Cederberg H	Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort.	Diabetologia	2015	35
25766618	3630	Kim B	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome.	Experimental and molecular medicine	2015	20
25894657	3630	Neis EP	The role of microbial amino acid metabolism in host metabolism.	Nutrients	2015	28
26050667	3630	Betz MJ	Human Brown Adipose Tissue: What We Have Learned So Far.	Diabetes	2015	21
26077431	3630	Rönn T	DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes.	Epigenomics	2015	17
26319013	3630	Negro F	Extrahepatic morbidity and mortality of chronic hepatitis C.	Gastroenterology	2015	19
26549485	3630	Tian XY	Thermoneutral Housing Accelerates Metabolic Inflammation to Potentiate Atherosclerosis but Not Insulin Resistance.	Cell metabolism	2016	13
26628415	3630	Henson J	Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study.	Diabetes care	2016	13
26678809	3630	Jia G	Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.	Nature reviews. Endocrinology	2016	25
26784127	3630	Rodbard D	Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities.	Diabetes technology and therapeutics	2016	17
26886418	3630	Kernan WN	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.	The New England journal of medicine	2016	45
27256476	3630	Kusminski CM	Targeting adipose tissue in the treatment of obesity-associated diabetes.	Nature reviews. Drug discovery	2016	13
27409811	3630	Pedersen HK	Human gut microbes impact host serum metabolome and insulin sensitivity.	Nature	2016	31
27739515	3630	Sylow L	Exercise-stimulated glucose uptake - regulation and implications for glycaemic control.	Nature reviews. Endocrinology	2017	8
28118453	3630	Beck RW	Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.	JAMA	2017	17
28118454	3630	Lind M	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.	JAMA	2017	11
7997262	3643	Hubbard SR	Crystal structure of the tyrosine kinase domain of the human insulin receptor.	Nature	1994	182
10905472	3643	Kelley DE	Fuel selection in human skeletal muscle in insulin resistance: a reexamination.	Diabetes	2000	163
17167487	3643	Hafner M	Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance.	Nature	2006	72
19897683	3643	Skarulis MC	Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insulin resistance.	The Journal of clinical endocrinology and metabolism	2010	43
16460677	3651	Timper K	Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells.	Biochemical and biophysical research communications	2006	72
19255591	3651	Zhang D	Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells.	Cell research	2009	137
22570331	3651	Yang BT	Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes.	Molecular endocrinology	2012	50
23434589	3651	Bramswig NC	Epigenomic plasticity enables human pancreatic α to β cell reprogramming.	The Journal of clinical investigation	2013	104
24613355	3651	Chen YJ	De novo formation of insulin-producing "neo-β cell islets" from intestinal crypts.	Cell reports	2014	26
24633305	3651	Ardestani A	MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes.	Nature medicine	2014	34
25908839	3651	Russ HA	Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro.	The EMBO journal	2015	45
25918235	3651	Spijker HS	Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits.	Diabetes	2015	17
12351658	3667	Gao Z	Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex.	The Journal of biological chemistry	2002	161
12765939	3667	Bouzakri K	Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes.	Diabetes	2003	80
17130651	3667	Morino K	Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.	Diabetes	2006	192
19734900	3667	Rung J	Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia.	Nature genetics	2009	150
23400783	3667	Brännmark C	Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes.	The Journal of biological chemistry	2013	28
15115830	3767	Gloyn AL	Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.	The New England journal of medicine	2004	230
16123337	3767	Hattersley AT	Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy.	Diabetes	2005	84
16885550	3767	Pearson ER	Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.	The New England journal of medicine	2006	189
17020404	3767	Weedon MN	Combining information from common type 2 diabetes risk polymorphisms improves disease prediction.	PLoS medicine	2006	93
17446535	3767	Flanagan SE	Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood.	Diabetes	2007	70
17977958	3767	Vaxillaire M	Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study.	Diabetes	2008	57
18767144	3767	Flanagan SE	Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism.	Human mutation	2009	66
21049026	3767	Bonnefond A	Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome.	PloS one	2010	42
8684156	3952	Caro JF	Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.	Lancet	1996	126
11342529	3952	Yamagishi SI	Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A.	The Journal of biological chemistry	2001	97
11797013	3952	Minokoshi Y	Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase.	Nature	2002	350
11818477	3952	Unger RH	Lipotoxic diseases.	Annual review of medicine	2002	173
11856796	3952	Oral EA	Leptin-replacement therapy for lipodystrophy.	The New England journal of medicine	2002	197
12021250	3952	Petersen KF	Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.	The Journal of clinical investigation	2002	166
14749508	3952	Bjørbaek C	Leptin signaling in the central nervous system and the periphery.	Recent progress in hormone research	2004	94
15070752	3952	Licinio J	Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults.	Proceedings of the National Academy of Sciences of the United States of America	2004	86
15971409	3952	Havel PJ	Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism.	Nutrition reviews	2005	137
16110483	3952	Garofalo C	Leptin and cancer.	Journal of cellular physiology	2006	128
16932309	3952	Brennan AM	Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications.	Nature clinical practice. Endocrinology and metabolism	2006	66
19171638	3952	Mantzoros CS	Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a prospective cohort study.	Pediatrics	2009	52
20413520	3952	Mente A	Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance.	Diabetes care	2010	44
20600241	3952	Dardeno TA	Leptin in human physiology and therapeutics.	Frontiers in neuroendocrinology	2010	51
20724651	3952	Bouchard L	Leptin gene epigenetic adaptation to impaired glucose metabolism during pregnancy.	Diabetes care	2010	50
22935803	3952	Coppari R	Leptin revisited: its mechanism of action and potential for treating diabetes.	Nature reviews. Drug discovery	2012	65
23466711	3952	Duggan C	Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.	Clinical gastroenterology and hepatology 	2013	37
24768298	3952	Luan B	Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4.	Cell metabolism	2014	24
25199978	3952	Park HK	Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism.	Metabolism	2015	35
25800063	3952	Allard C	Mendelian randomization supports causality between maternal hyperglycemia and epigenetic regulation of leptin gene in newborns.	Epigenetics	2015	15
18454148	4160	Loos RJ	Common variants near MC4R are associated with fat mass, weight and risk of obesity.	Nature genetics	2008	403
18697794	4160	Qi L	The common obesity variant near MC4R gene is associated with higher intakes of total energy and dietary fat, weight change and diabetes risk in women.	Human molecular genetics	2008	52
19255736	4160	Cauchi S	Combined effects of MC4R and FTO common genetic variants on obesity in European general populations.	Journal of molecular medicine	2009	49
19557197	4160	Heard-Costa NL	NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium.	PLoS genetics	2009	95
23048186	4160	Kievit P	Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.	Diabetes	2013	32
26814590	4160	Krashes MJ	Melanocortin-4 receptor-regulated energy homeostasis.	Nature neuroscience	2016	19
16585403	4846	Förstermann U	Endothelial nitric oxide synthase in vascular disease: from marvel to menace.	Circulation	2006	327
17327434	4846	Thum T	Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes.	Diabetes	2007	101
18382884	4846	Münzel T	Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction.	Annals of medicine	2008	76
21471513	4846	Godfrey KM	Epigenetic gene promoter methylation at birth is associated with child's later adiposity.	Diabetes	2011	151
21838680	4846	Folli F	The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach.	Current diabetes reviews	2011	42
15564564	4982	Collin-Osdoby P	Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.	Circulation research	2004	76
21676245	4982	Cao JJ	Effects of obesity on bone metabolism.	Journal of orthopaedic surgery and research	2011	85
11071182	5054	Anand SS	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)	Lancet	2000	179
17620421	5054	Kolak M	Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity.	Diabetes	2007	78
18065585	5054	Kabir M	Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study.	The American journal of clinical nutrition	2007	57
23704675	5054	TODAY Study Group.	Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial.	Diabetes care	2013	26
15920049	5187	Egede LE	Depression and all-cause and coronary heart disease mortality among adults with and without diabetes.	Diabetes care	2005	95
18584872	5187	Wong TY	Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study.	Ophthalmology	2008	55
19752089	5187	Cao Q	A role for the clock gene per1 in prostate cancer.	Cancer research	2009	46
20576628	5187	Wijndaele K	Television viewing time independently predicts all-cause and cardiovascular mortality: the EPIC Norfolk study.	International journal of epidemiology	2011	70
20843952	5187	Liu J	Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study.	The Journal of clinical endocrinology and metabolism	2010	79
25190234	5187	Chandra A	The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study.	Journal of the American College of Cardiology	2014	23
20934178	5444	Précourt LP	The three-gene paraoxonase family: physiologic roles, actions and regulation.	Atherosclerosis	2011	43
9748221	5465	Chinetti G	Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.	The Journal of biological chemistry	1998	152
15522914	5465	Sharma S	Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart.	FASEB journal 	2004	173
16447287	5465	Farrell GC	Nonalcoholic fatty liver disease: from steatosis to cirrhosis.	Hepatology	2006	470
17428730	5465	Rubenstrunk A	Safety issues and prospects for future generations of PPAR modulators.	Biochimica et biophysica acta	2007	68
18510434	5465	Swarbrick MM	Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans.	Metabolic syndrome and related disorders	2008	63
19515415	5465	Henry RR	Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.	Lancet	2009	47
19923038	5465	Sato T	Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.	Neurobiology of aging	2011	72
20346437	5465	Zhong H	Integrating pathway analysis and genetics of gene expression for genome-wide association studies.	American journal of human genetics	2010	124
9806549	5468	Deeb SS	A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.	Nature genetics	1998	232
10622252	5468	Barroso I	Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.	Nature	1999	217
11395411	5468	Willson TM	Peroxisome proliferator-activated receptor gamma and metabolic disease.	Annual review of biochemistry	2001	112
12663460	5468	Savage DB	Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.	Diabetes	2003	77
15277403	5468	Tiikkainen M	Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.	Diabetes	2004	74
16214598	5468	Dormandy JA	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.	Lancet	2005	496
16360030	5468	Lehrke M	The many faces of PPARgamma.	Cell	2005	304
16936206	5468	Tchkonia T	Fat depot-specific characteristics are retained in strains derived from single human preadipocytes.	Diabetes	2006	69
18325386	5468	Lewis JD	Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.	Gastroenterology	2008	62
19392647	5468	Rosen CJ	Marrow fat and the bone microenvironment: developmental, functional, and pathological implications.	Critical reviews in eukaryotic gene expression	2009	93
19906796	5468	Higgins LS	Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.	The American journal of clinical nutrition	2010	44
20051526	5468	Manolagas SC	From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.	Endocrine reviews	2010	159
20179158	5468	Gouda HN	The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.	American journal of epidemiology	2010	52
21251979	5468	Janesick A	Minireview: PPARγ as the target of obesogens.	The Journal of steroid biochemistry and molecular biology	2011	38
25157153	5468	Majithia AR	Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.	Proceedings of the National Academy of Sciences of the United States of America	2014	30
26140591	5468	Soccio RE	Genetic Variation Determines PPARγ Function and Anti-diabetic Drug Response In Vivo.	Cell	2015	24
14729328	5563	Carling D	The AMP-activated protein kinase cascade--a unifying system for energy control.	Trends in biochemical sciences	2004	217
19196246	5563	Richter EA	AMPK and the biochemistry of exercise: implications for human health and disease.	The Biochemical journal	2009	83
21130749	5563	Gauthier MS	Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans.	Biochemical and biophysical research communications	2011	45
22315316	5563	Martínez de Morentin PB	Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase.	Diabetes	2012	35
22702974	5563	Carling D	AMP-activated protein kinase: new regulation, new roles?	The Biochemical journal	2012	79
23801715	5563	Hardie DG	AMPK: a target for drugs and natural products with effects on both diabetes and cancer.	Diabetes	2013	60
23835523	5563	Rena G	Molecular mechanism of action of metformin: old or new insights?	Diabetologia	2013	69
25018645	5563	Coughlan KA	AMPK activation: a therapeutic target for type 2 diabetes?	Diabetes, metabolic syndrome and obesity 	2014	37
15814832	5741	Slinin Y	Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.	Journal of the American Society of Nephrology 	2005	76
16316359	5741	Agarwal R	Antiproteinuric effect of oral paricalcitol in chronic kidney disease.	Kidney international	2005	84
16563471	5741	Lips P	Vitamin D physiology.	Progress in biophysics and molecular biology	2006	166
16600341	5741	Zittermann A	Vitamin D and disease prevention with special reference to cardiovascular disease.	Progress in biophysics and molecular biology	2006	79
17091124	5741	Levin A	Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.	Kidney international	2007	242
19451355	5741	Hagström E	Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.	Circulation	2009	82
22473330	5741	Thompson B	Arterial calcification and bone physiology: role of the bone-vascular axis.	Nature reviews. Endocrinology	2012	44
17065684	5950	Cho YM	Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes.	Diabetes care	2006	81
21835764	5950	Kotnik P	RBP4: a controversial adipokine.	European journal of endocrinology	2011	43
23105095	5950	Alapatt P	Liver retinol transporter and receptor for serum retinol-binding protein (RBP4).	The Journal of biological chemistry	2013	27
18256393	5972	Gaede P	Effect of a multifactorial intervention on mortality in type 2 diabetes.	The New England journal of medicine	2008	502
18525041	5972	Parving HH	Aliskiren combined with losartan in type 2 diabetes and nephropathy.	The New England journal of medicine	2008	178
18823656	5972	Chaturvedi N	Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.	Lancet	2008	66
19005010	5972	Moranne O	Timing of onset of CKD-related metabolic complications.	Journal of the American Society of Nephrology 	2009	70
19289633	5972	Böger RH	Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.	Circulation	2009	61
22945249	5972	Damasceno A	The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries.	Archives of internal medicine	2012	61
23121378	5972	Parving HH	Cardiorenal end points in a trial of aliskiren for type 2 diabetes.	The New England journal of medicine	2012	133
23478743	5972	Gheorghiade M	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.	JAMA	2013	30
24334175	5972	Cherney DZ	Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.	Circulation	2014	105
25349246	5972	Ding Y	Autophagy in diabetic nephropathy.	The Journal of endocrinology	2015	23
25801871	5972	Pilz S	Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial.	Hypertension	2015	21
11874924	6240	van Dam RM	Dietary fat and meat intake in relation to risk of type 2 diabetes in men.	Diabetes care	2002	112
17476474	6240	Friberg E	Diabetes mellitus and risk of endometrial cancer: a meta-analysis.	Diabetologia	2007	90
18076931	6240	Thompson RH	Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.	The Journal of urology	2008	95
23437258	6240	Lv Q	High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies.	PloS one	2013	28
25481707	6240	Levin D	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.	Diabetologia	2015	24
26453266	6240	Qin J	Assisted reproductive technology and the risk of pregnancy-related complications and adverse pregnancy outcomes in singleton pregnancies: a meta-analysis of cohort studies.	Fertility and sterility	2016	14
15111517	6462	Laaksonen DE	Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.	Diabetes care	2004	118
16537739	6462	Ding EL	Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.	JAMA	2006	235
19657112	6462	Ding EL	Sex hormone-binding globulin and risk of type 2 diabetes in women and men.	The New England journal of medicine	2009	139
19933169	6462	Perry JR	Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes.	Human molecular genetics	2010	44
20573783	6462	Krassas GE	Thyroid function and human reproductive health.	Endocrine reviews	2010	91
23425925	6462	Camacho EM	Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study.	European journal of endocrinology	2013	36
14683737	6476	Hanefeld M	Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.	European heart journal	2004	76
22129971	6476	Lai SW	Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan.	Clinical lung cancer	2012	36
11424232	6517	Rösen P	The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society.	Diabetes/metabolism research and reviews	2001	109
23139352	6517	Boon J	Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance.	Diabetes	2013	39
26147760	6517	Hanssen MJ	Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus.	Nature medicine	2015	33
26718499	6517	Hanssen MJ	Short-term Cold Acclimation Recruits Brown Adipose Tissue in Obese Humans.	Diabetes	2016	14
26972823	6517	Lee P	Brown Adipose Tissue Exhibits a Glucose-Responsive Thermogenic Biorhythm in Humans.	Cell metabolism	2016	11
19129748	6524	Komoroski B	Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.	Clinical pharmacology and therapeutics	2009	53
19129749	6524	Komoroski B	Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.	Clinical pharmacology and therapeutics	2009	60
19357717	6524	Bakris GL	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.	Kidney international	2009	47
20546255	6524	Gerich JE	Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.	Diabetic medicine 	2010	67
20609968	6524	Bailey CJ	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.	Lancet	2010	134
21672123	6524	Strojek K	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.	Diabetes, obesity and metabolism	2011	73
21816980	6524	Nauck MA	Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.	Diabetes care	2011	87
22238392	6524	Bolinder J	Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.	The Journal of clinical endocrinology and metabolism	2012	94
22310849	6524	Ferrannini E	SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.	Nature reviews. Endocrinology	2012	41
22446170	6524	Rosenstock J	Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.	Diabetes care	2012	61
23564919	6524	Schernthaner G	Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.	Diabetes care	2013	85
23735727	6524	DeFronzo RA	Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.	Diabetes care	2013	32
23806570	6524	Johnsson KM	Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.	Journal of diabetes and its complications	2013	31
23849632	6524	Johnsson KM	Urinary tract infections in patients with diabetes treated with dapagliflozin.	Journal of diabetes and its complications	2013	31
23895803	6524	Neal B	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.	American heart journal	2013	60
23911013	6524	Wilding JP	Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.	Diabetes, obesity and metabolism	2014	40
24067431	6524	Kohan DE	Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.	Kidney international	2014	68
24186878	6524	Ferrannini E	Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.	Diabetes care	2013	29
24463454	6524	Ferrannini E	Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.	The Journal of clinical investigation	2014	91
24475922	6524	Cherney DZ	The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.	Cardiovascular diabetology	2014	43
24595630	6524	Perkins BA	Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.	Diabetes care	2014	32
24602971	6524	Baker WL	Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.	Journal of the American Society of Hypertension 	2014	43
24631482	6524	Oliva RV	Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.	Journal of the American Society of Hypertension 	2014	33
24673844	6524	De Nicola L	Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.	American journal of kidney diseases 	2014	23
24766495	6524	Liakos A	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.	Diabetes, obesity and metabolism	2014	28
24918789	6524	Usiskin K	Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.	Postgraduate medicine	2014	27
25205142	6524	Leiter LA	Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.	Diabetes care	2015	37
25246775	6524	Nauck MA	Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.	Drug design, development and therapy	2014	32
25271207	6524	Henry RR	Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.	Diabetes care	2015	31
25341005	6524	Vallon V	The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.	Annual review of medicine	2015	18
25488697	6524	Scheen AJ	Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.	Drugs	2015	22
26078479	6524	Peters AL	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.	Diabetes care	2015	48
26086329	6524	Taylor SI	SGLT2 Inhibitors May Predispose to Ketoacidosis.	The Journal of clinical endocrinology and metabolism	2015	43
26305874	6524	Rosenthal N	Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.	Annals of the New York Academy of Sciences	2015	17
26378978	6524	Zinman B	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.	The New England journal of medicine	2015	305
26580237	6524	Watts NB	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.	The Journal of clinical endocrinology and metabolism	2016	20
26604280	6524	Mudaliar S	Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.	Diabetes care	2015	18
26620248	6524	Weber MA	Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.	The lancet. Diabetes and endocrinology	2016	15
26861783	6524	Ferrannini E	Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.	Diabetes	2016	15
26895767	6524	Sonesson C	Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.	Cardiovascular diabetology	2016	19
27042263	6524	Ogawa W	Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.	Journal of diabetes investigation	2016	15
27208375	6524	Abdul-Ghani M	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.	Diabetes care	2016	23
27289126	6524	Ferrannini E	CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.	Diabetes care	2016	24
27470878	6524	Heerspink HJ	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.	Circulation	2016	17
24915262	6927	SIGMA Type 2 Diabetes Consortium.	Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population.	JAMA	2014	35
17603485	6928	Gudmundsson J	Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.	Nature genetics	2007	311
21055719	6928	Moreno-De-Luca D	Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia.	American journal of human genetics	2010	84
16855264	6934	Florez JC	TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.	The New England journal of medicine	2006	223
17093941	6934	Chandak GR	Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population.	Diabetologia	2007	59
17519421	6934	Pearson ER	Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.	Diabetes	2007	64
17661009	6934	Schäfer SA	Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.	Diabetologia	2007	79
17671651	6934	Lyssenko V	Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.	The Journal of clinical investigation	2007	191
18071026	6934	Shu L	Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets.	Diabetes	2008	84
19168596	6934	da Silva Xavier G	TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells.	Diabetes	2009	65
19228405	6934	Tong Y	Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis.	BMC medical genetics	2009	56
20118932	6934	Gaulton KJ	A map of open chromatin in human pancreatic islets.	Nature genetics	2010	198
9054939	7350	Fleury C	Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia.	Nature genetics	1997	194
19357406	7350	Cypess AM	Identification and importance of brown adipose tissue in adult humans.	The New England journal of medicine	2009	834
21375707	7350	Nedergaard J	Three years with adult human brown adipose tissue.	Annals of the New York Academy of Sciences	2010	46
23603815	7350	Cypess AM	Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat.	Nature medicine	2013	151
25487280	7350	Moisan A	White-to-brown metabolic conversion of human adipocytes by JAK inhibition.	Nature cell biology	2015	23
26050668	7350	Stanford KI	Exercise Effects on White Adipose Tissue: Beiging and Metabolic Adaptations.	Diabetes	2015	20
26050670	7350	Cohen P	Brown and Beige Fat: Molecular Parts of a Thermogenic Machine.	Diabetes	2015	27
26912151	7350	Kim SH	Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders.	Diabetes and metabolism journal	2016	10
12520530	7421	Holick MF	Vitamin D: A millenium perspective.	Journal of cellular biochemistry	2003	196
15315818	7421	Uitterlinden AG	Genetics and biology of vitamin D receptor polymorphisms.	Gene	2004	210
15971062	7421	Mathieu C	Vitamin D and diabetes.	Diabetologia	2005	87
18269634	7421	Palomer X	Role of vitamin D in the pathogenesis of type 2 diabetes mellitus.	Diabetes, obesity and metabolism	2008	71
18579197	7421	Buell JS	Vitamin D and neurocognitive dysfunction: preventing "D"ecline?	Molecular aspects of medicine	2008	58
18801384	7421	Holick MF	The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action.	Molecular aspects of medicine	2008	57
20736230	7421	Ramagopalan SV	A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution.	Genome research	2010	209
20795941	7421	Holick MF	Vitamin D: evolutionary, physiological and health perspectives.	Current drug targets	2011	63
20863562	7421	Shin JS	Vitamin D effects on pregnancy and the placenta.	Placenta	2010	43
22596255	7421	Rosen CJ	The nonskeletal effects of vitamin D: an Endocrine Society scientific statement.	Endocrine reviews	2012	108
24108316	7421	Ceglia L	A randomized study on the effect of vitamin D₃ supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women.	The Journal of clinical endocrinology and metabolism	2013	31
25073467	7421	Li T	Bile acid signaling in metabolic disease and drug therapy.	Pharmacological reviews	2014	56
25259922	7421	Sherman MH	Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.	Cell	2014	94
7759509	7422	Frank S	Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing.	The Journal of biological chemistry	1995	119
11978667	7422	Awata T	A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.	Diabetes	2002	84
12941734	7422	Ciulla TA	Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.	Diabetes care	2003	94
15149314	7422	Schrijvers BF	The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.	Kidney international	2004	90
15161630	7422	Galiano RD	Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells.	The American journal of pathology	2004	136
16154196	7422	Cunningham ET Jr	A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.	Ophthalmology	2005	106
16193288	7422	Perrin RM	Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.	Diabetologia	2005	70
16364190	7422	Byrne AM	Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).	Journal of cellular and molecular medicine	2005	141
16518379	7422	Ng EW	Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.	Nature reviews. Drug discovery	2006	206
16828580	7422	Borzychowski AM	Inflammation and pre-eclampsia.	Seminars in fetal and neonatal medicine	2006	89
17046701	7422	Nguyen QD	Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.	American journal of ophthalmology	2006	69
17475821	7422	Lindenmeyer MT	Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy.	Journal of the American Society of Nephrology 	2007	69
17674014	7422	Wu L	Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).	Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie	2008	72
18163003	7422	Andreoli CM	Anti-vascular endothelial growth factor therapy for ocular neovascular disease.	Current opinion in ophthalmology	2007	59
18653375	7422	Penn JS	Vascular endothelial growth factor in eye disease.	Progress in retinal and eye research	2008	132
19027922	7422	Bao P	The role of vascular endothelial growth factor in wound healing.	The Journal of surgical research	2009	110
19666581	7422	Thangarajah H	The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
20980427	7422	Massin P	Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.	Diabetes care	2010	114
21529957	7422	Sultan MB	A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.	Ophthalmology	2011	38
21546089	7422	Do DV	The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.	Ophthalmology	2011	55
21752957	7422	Woroniecka KI	Transcriptome analysis of human diabetic kidney disease.	Diabetes	2011	93
22330964	7422	Nguyen QD	Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.	Ophthalmology	2012	171
22537617	7422	Do DV	One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.	Ophthalmology	2012	64
23385630	7422	Zehetner C	Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.	The British journal of ophthalmology	2013	26
23706949	7422	Brown DM	Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.	Ophthalmology	2013	85
24525867	7422	Osaadon P	A review of anti-VEGF agents for proliferative diabetic retinopathy.	Eye	2014	23
24673341	7422	Abcouwer SF	Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment.	Annals of the New York Academy of Sciences	2014	24
25012934	7422	Korobelnik JF	Intravitreal aflibercept for diabetic macular edema.	Ophthalmology	2014	56
25204977	7422	Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.	Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.	Diabetes	2015	28
25342124	7422	Virgili G	Anti-vascular endothelial growth factor for diabetic macular oedema.	The Cochrane database of systematic reviews	2014	30
25896459	7422	Ishibazawa A	Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study.	American journal of ophthalmology	2015	50
25935789	7422	Das A	Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.	Ophthalmology	2015	25
26935357	7422	Wells JA	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.	Ophthalmology	2016	26
9771706	7466	Inoue H	A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome).	Nature genetics	1998	113
8432214	8991	Stamler J	Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.	Diabetes care	1993	454
18258416	8991	Meyer JM	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.	Schizophrenia research	2008	54
20029377	8991	Perez-Pozo SE	Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response.	International journal of obesity	2010	58
10845877	9370	Hotta K	Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.	Arteriosclerosis, thrombosis, and vascular biology	2000	433
11334417	9370	Hotta K	Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys.	Diabetes	2001	131
11502817	9370	Yang WS	Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin.	The Journal of clinical endocrinology and metabolism	2001	125
12114044	9370	Lindsay RS	Adiponectin and development of type 2 diabetes in the Pima Indian population.	Lancet	2002	143
12354786	9370	Vasseur F	Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians.	Human molecular genetics	2002	94
12524229	9370	Kumada M	Association of hypoadiponectinemia with coronary artery disease in men.	Arteriosclerosis, thrombosis, and vascular biology	2003	215
12540592	9370	Tschritter O	Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism.	Diabetes	2003	94
12611609	9370	Díez JJ	The role of the novel adipocyte-derived hormone adiponectin in human disease.	European journal of endocrinology	2003	150
12829629	9370	Iwaki M	Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors.	Diabetes	2003	133
12878598	9370	Waki H	Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin.	The Journal of biological chemistry	2003	173
14699128	9370	Pajvani UB	Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.	The Journal of biological chemistry	2004	226
15123570	9370	Iwashima Y	Hypoadiponectinemia is an independent risk factor for hypertension.	Hypertension	2004	111
15181024	9370	Goldstein BJ	Adiponectin: A novel adipokine linking adipocytes and vascular function.	The Journal of clinical endocrinology and metabolism	2004	105
16380500	9370	Lara-Castro C	Adiponectin multimeric complexes and the metabolic syndrome trait cluster.	Diabetes	2006	103
16464169	9370	Okamoto Y	Adiponectin: a key adipocytokine in metabolic syndrome.	Clinical science	2006	86
16732021	9370	Hara K	Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome.	Diabetes care	2006	104
17192291	9370	Körner A	Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.	The Journal of clinical endocrinology and metabolism	2007	57
17224929	9370	Côté M	Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.	International journal of obesity	2007	67
17374708	9370	Anderson PD	Innate immunity modulates adipokines in humans.	The Journal of clinical endocrinology and metabolism	2007	56
17495599	9370	Lara-Castro C	Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.	Current opinion in lipidology	2007	61
17557769	9370	West SD	Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes.	Thorax	2007	83
17981890	9370	Rose DP	Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women.	Endocrine reviews	2007	68
18061654	9370	Fantuzzi G	Adiponectin and inflammation: consensus and controversy.	The Journal of allergy and clinical immunology	2008	79
18202126	9370	Schraw T	Plasma adiponectin complexes have distinct biochemical characteristics.	Endocrinology	2008	53
18405959	9370	Shore SA	Obesity and asthma: possible mechanisms.	The Journal of allergy and clinical immunology	2008	85
18503774	9370	Ratziu V	Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.	Gastroenterology	2008	97
19083400	9370	Kajiyama S	Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance.	Nutrition research	2008	61
19106328	9370	Liu E	Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults.	The Journal of nutrition	2009	69
19584347	9370	Li S	Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis.	JAMA	2009	215
19756488	9370	Finucane FM	Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals.	Diabetologia	2009	60
19833885	9370	Karakelides H	Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function.	Diabetes	2010	62
20018283	9370	Heid IM	Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals.	Atherosclerosis	2010	57
20644557	9370	Misra A	Obesity-related non-communicable diseases: South Asians vs White Caucasians.	International journal of obesity	2011	61
21040935	9370	Polyzos SA	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.	Metabolism	2011	38
22479202	9370	Dastani Z	Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.	PLoS genetics	2012	130
22547160	9370	Dalamaga M	The role of adiponectin in cancer: a review of current evidence.	Endocrine reviews	2012	85
23781214	9370	Kwon H	Adipokines mediate inflammation and insulin resistance.	Frontiers in endocrinology	2013	62
23817699	9370	Goldfine AB	Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.	Annals of internal medicine	2013	48
24954193	9370	Lee P	Temperature-acclimated brown adipose tissue modulates insulin sensitivity in humans.	Diabetes	2014	56
26978208	9370	Tyrrell J	Genetic Evidence for Causal Relationships Between Maternal Obesity-Related Traits and Birth Weight.	JAMA	2016	19
26993044	9370	Ruan H	Adiponectin signaling and function in insulin target tissues.	Journal of molecular cell biology	2016	20
15604363	10135	Fukuhara A	Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.	Science	2005	272
16186392	10135	Berndt J	Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.	Diabetes	2005	87
16234302	10135	Chen MP	Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.	The Journal of clinical endocrinology and metabolism	2006	79
16311215	10135	Koerner A	Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come.	Best practice and research. Clinical endocrinology and metabolism	2005	73
16496121	10135	Curat CA	Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin.	Diabetologia	2006	89
18093861	10135	Antuna-Puente B	Adipokines: the missing link between insulin resistance and obesity.	Diabetes and metabolism	2008	108
18987272	10135	Rasouli N	Adipocytokines and the metabolic complications of obesity.	The Journal of clinical endocrinology and metabolism	2008	126
19887595	10135	Costford SR	Skeletal muscle NAMPT is induced by exercise in humans.	American journal of physiology. Endocrinology and metabolism	2010	46
20068143	10135	de Kreutzenberg SV	Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms.	Diabetes	2010	56
21377179	10135	Jorge ML	The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus.	Metabolism	2011	41
24003918	10135	Imai S	The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing.	Diabetes, obesity and metabolism	2013	29
26215259	10135	Garten A	Physiological and pathophysiological roles of NAMPT and NAD metabolism.	Nature reviews. Endocrinology	2015	23
15705778	10628	Minn AH	Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis.	Endocrinology	2005	102
17472435	10628	Parikh H	TXNIP regulates peripheral glucose metabolism in humans.	PLoS medicine	2007	125
19411249	10628	Cha-Molstad H	Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells.	The Journal of biological chemistry	2009	64
22883234	10628	Oslowski CM	Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome.	Cell metabolism	2012	107
26095709	10628	Chambers JC	Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study.	The lancet. Diabetes and endocrinology	2015	38
26433941	10628	Florath I	Type 2 diabetes and leucocyte DNA methylation: an epigenome-wide association study in over 1,500 older adults.	Diabetologia	2016	11
17827400	10644	Grarup N	Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies.	Diabetes	2007	92
18984664	10644	Lauenborg J	Common type 2 diabetes risk gene variants associate with gestational diabetes.	The Journal of clinical endocrinology and metabolism	2009	49
11148210	10724	Gao Y	Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain.	The Journal of biological chemistry	2001	144
20488252	10724	Love DC	O-GlcNAc cycling: emerging roles in development and epigenetics.	Seminars in cell and developmental biology	2010	41
22128088	10724	Lunde IG	Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.	Physiological genomics	2012	37
23647930	10724	Ruan HB	Cracking the O-GlcNAc code in metabolism.	Trends in endocrinology and metabolism	2013	45
12807871	10891	Tiraby C	Acquirement of brown fat cell features by human white adipocytes.	The Journal of biological chemistry	2003	97
12808457	10891	Mootha VK	PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.	Nature genetics	2003	1654
12832613	10891	Patti ME	Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.	Proceedings of the National Academy of Sciences of the United States of America	2003	497
12882902	10891	Short KR	Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity.	Diabetes	2003	131
14633846	10891	Russell AP	Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle.	Diabetes	2003	104
14744933	10891	Fan M	Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK.	Genes and development	2004	86
15087503	10891	Schreiber SN	The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2004	155
15100410	10891	Mootha VK	Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle.	Proceedings of the National Academy of Sciences of the United States of America	2004	218
15855325	10891	Bogacka I	Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo.	Diabetes	2005	103
15914121	10891	Valle I	PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells.	Cardiovascular research	2005	115
16380484	10891	Kukidome D	Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells.	Diabetes	2006	132
17567459	10891	Pessayre D	Role of mitochondria in non-alcoholic fatty liver disease.	Journal of gastroenterology and hepatology	2007	59
17704301	10891	Westerbacka J	Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects.	Diabetes	2007	79
18198341	10891	Olson BL	SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis.	Genes and development	2008	59
18270681	10891	Ling C	Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion.	Diabetologia	2008	98
18393104	10891	Elliott PJ	Sirtuins: novel targets for metabolic disease.	Current opinion in investigational drugs	2008	53
19433800	10891	Ristow M	Antioxidants prevent health-promoting effects of physical exercise in humans.	Proceedings of the National Academy of Sciences of the United States of America	2009	302
19723495	10891	Barrès R	Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density.	Cell metabolism	2009	139
19853062	10891	Spindler SR	Caloric restriction: from soup to nuts.	Ageing research reviews	2010	58
20032281	10891	Hernández-Alvarez MI	Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity.	Diabetes care	2010	45
20371735	10891	Lira VA	PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity.	American journal of physiology. Endocrinology and metabolism	2010	60
20585248	10891	Bournat JC	Mitochondrial dysfunction in obesity.	Current opinion in endocrinology, diabetes, and obesity	2010	48
21266331	10891	Elbein SC	Global gene expression profiles of subcutaneous adipose and muscle from glucose-tolerant, insulin-sensitive, and insulin-resistant individuals matched for BMI.	Diabetes	2011	36
22323564	10891	Xu XJ	Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue.	Journal of lipid research	2012	40
22446165	10891	Chowdhury SK	The role of aberrant mitochondrial bioenergetics in diabetic neuropathy.	Neurobiology of disease	2013	36
23104101	10891	Morris BJ	Seven sirtuins for seven deadly diseases of aging.	Free radical biology and medicine	2013	61
23949796	10891	Sharma K	Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease.	Journal of the American Society of Nephrology 	2013	61
24237962	10891	Norheim F	The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans.	The FEBS journal	2014	49
24506866	10891	Sawada N	Endothelial PGC-1α mediates vascular dysfunction in diabetes.	Cell metabolism	2014	27
24606795	10891	Valero T	Mitochondrial biogenesis: pharmacological approaches.	Current pharmaceutical design	2014	24
24722248	10891	Kurtz CL	MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes.	Diabetes	2014	24
25605802	10891	Gustafson B	BMP4 and BMP Antagonists Regulate Human White and Beige Adipogenesis.	Diabetes	2015	18
15823385	11132	Stumvoll M	Type 2 diabetes: principles of pathogenesis and therapy.	Lancet	2005	332
12479764	22796	ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.	Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).	JAMA	2002	175
18317847	22796	Schmittdiel JA	Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification.	Journal of general internal medicine	2008	74
19546386	22796	Waters DD	Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.	Circulation	2009	62
26227186	22796	Tsujita K	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.	Journal of the American College of Cardiology	2015	16
15768047	23411	Bordone L	Calorie restriction, SIRT1 and metabolism: understanding longevity.	Nature reviews. Molecular cell biology	2005	260
18835033	23411	Wang RH	Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.	Cancer cell	2008	247
19107194	23411	Sasaki T	Phosphorylation regulates SIRT1 function.	PloS one	2008	98
19286634	23411	Orimo M	Protective role of SIRT1 in diabetic vascular dysfunction.	Arteriosclerosis, thrombosis, and vascular biology	2009	47
19455179	23411	Liang F	SIRT1 and insulin resistance.	Nature reviews. Endocrinology	2009	69
20078221	23411	Haigis MC	Mammalian sirtuins: biological insights and disease relevance.	Annual review of pathology	2010	460
20409078	23411	Donmez G	Aging and disease: connections to sirtuins.	Aging cell	2010	115
21778425	23411	Zhou S	Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction.	Circulation research	2011	44
22479251	23411	Yamakuchi M	MicroRNA Regulation of SIRT1.	Frontiers in physiology	2012	38
22553202	23411	Nin V	Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.	The Journal of biological chemistry	2012	38
23193181	23411	Poulsen MM	High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.	Diabetes	2013	82
23473037	23411	Biason-Lauber A	Identification of a SIRT1 mutation in a family with type 1 diabetes.	Cell metabolism	2013	26
23932046	23411	Palomer X	An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.	International journal of cardiology	2013	30
24160699	23411	Sinclair DA	Small-molecule allosteric activators of sirtuins.	Annual review of pharmacology and toxicology	2014	49
24184811	23411	Li Y	Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.	Gastroenterology	2014	33
24439680	23411	Hubbard BP	Small molecule SIRT1 activators for the treatment of aging and age-related diseases.	Trends in pharmacological sciences	2014	77
24567379	23411	Cai W	Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
25445538	23411	Szkudelski T	Resveratrol and diabetes: from animal to human studies.	Biochimica et biophysica acta	2015	15
15273934	26191	Kyogoku C	Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.	American journal of human genetics	2004	161
15934099	26191	Hinks A	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.	Arthritis and rheumatism	2005	71
16697661	26191	Bottini N	Role of PTPN22 in type 1 diabetes and other autoimmune diseases.	Seminars in immunology	2006	62
17068132	26291	Kharitonenkov A	The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.	Endocrinology	2007	153
18252893	26291	Zhang X	Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.	Diabetes	2008	164
18460341	26291	Arner P	FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity.	FEBS letters	2008	57
18680716	26291	Gälman C	The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.	Cell metabolism	2008	110
19487637	26291	Chavez AO	Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.	Diabetes care	2009	63
19702724	26291	Mraz M	Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.	Clinical endocrinology	2009	58
21194964	26291	Kharitonenkov A	FGF21 reloaded: challenges of a rapidly growing field.	Trends in endocrinology and metabolism	2011	41
23217254	26291	Angelin B	Circulating fibroblast growth factors as metabolic regulators--a critical appraisal.	Cell metabolism	2012	52
23736373	26291	Lee P	Functional thermogenic beige adipogenesis is inducible in human neck fat.	International journal of obesity	2014	46
24011069	26291	Gaich G	The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.	Cell metabolism	2013	101
24709036	26291	Gimeno RE	FGF21-based pharmacotherapy--potential utility for metabolic disorders.	Trends in endocrinology and metabolism	2014	35
25083607	26291	Fisher FM	Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.	Gastroenterology	2014	29
25476453	26291	Owen BM	Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.	Trends in endocrinology and metabolism	2015	35
26567701	26291	Degirolamo C	Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.	Nature reviews. Drug discovery	2016	17
26724861	26291	Talukdar S	FGF21 Regulates Sweet and Alcohol Preference.	Cell metabolism	2016	18
14499785	26503	Harrison SA	The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.	The American journal of gastroenterology	2003	85
18053320	26503	Klonoff DC	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.	Current medical research and opinion	2008	150
18390575	26503	Harrison SA	Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.	Gut	2008	92
20664019	26503	Lazo M	Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes.	Diabetes care	2010	49
20801772	26503	McPherson S	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.	Gut	2010	78
23387384	26503	Musso G	Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.	Obesity reviews 	2013	33
24436062	26503	Konerman MA	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.	Hepatology	2014	21
25645567	26503	Blonde L	Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.	Cardiovascular diabetology	2015	16
12504108	56729	Patel L	Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators.	Biochemical and biophysical research communications	2003	145
14557464	56729	Lee JH	Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects.	The Journal of clinical endocrinology and metabolism	2003	86
16039994	56729	Silswal N	Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway.	Biochemical and biophysical research communications	2005	94
18765700	56729	Heidemann C	Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women.	Annals of internal medicine	2008	61
19188682	56729	Qatanani M	Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice.	The Journal of clinical investigation	2009	45
21497511	56729	Schwartz DR	Human resistin: found in translation from mouse to man.	Trends in endocrinology and metabolism	2011	61
21545576	56729	Jamaluddin MS	Resistin: functional roles and therapeutic considerations for cardiovascular disease.	British journal of pharmacology	2012	36
17434869	79068	Frayling TM	A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.	Science	2007	1077
17703236	79068	Frayling TM	Genome-wide association studies provide new insights into type 2 diabetes aetiology.	Nature reviews. Genetics	2007	188
18335027	79068	Grant SF	Association analysis of the FTO gene with obesity in children of Caucasian and African ancestry reveals a common tagging SNP.	PloS one	2008	77
18599522	79068	Tan JT	FTO variants are associated with obesity in the Chinese and Malay populations in Singapore.	Diabetes	2008	55
19005641	79068	Yajnik CS	FTO gene variants are strongly associated with type 2 diabetes in South Asian Indians.	Diabetologia	2009	49
21994764	79068	Toperoff G	Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood.	Human molecular genetics	2012	94
25104851	79068	Qi Q	FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals.	Human molecular genetics	2014	28
19224197	80339	Kotronen A	A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.	Diabetologia	2009	69
19651814	80339	Kantartzis K	Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.	Diabetes	2009	71
20373368	80339	Valenti L	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology	2010	107
21319195	80339	Valenti L	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.	Hepatology	2011	62
21488075	80339	Trépo E	Impact of patatin-like phospholipase-3 (rs738409 C&amp;gt;G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C.	Hepatology	2011	51
24607626	80339	Liu YL	Carriage of the PNPLA3 rs738409 C &amp;gt;G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.	Journal of hepatology	2014	39
24731669	80339	Yki-Järvinen H	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.	The lancet. Diabetes and endocrinology	2014	67
19805629	114548	Lamkanfi M	Glyburide inhibits the Cryopyrin/Nalp3 inflammasome.	The Journal of cell biology	2009	151
20835230	114548	Masters SL	Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.	Nature immunology	2010	281
22948162	114548	Juliana C	Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation.	The Journal of biological chemistry	2012	98
23086037	114548	Lee HM	Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.	Diabetes	2013	78
23434541	114548	Chen K	ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy.	The international journal of biochemistry and cell biology	2013	28
23798679	114548	McGettrick AF	How metabolism generates signals during innate immunity and inflammation.	The Journal of biological chemistry	2013	38
23809162	114548	Yan Y	Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation.	Immunity	2013	71
23955712	114548	Jourdan T	Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes.	Nature medicine	2013	63
25686105	114548	Coll RC	A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.	Nature medicine	2015	119
25686106	114548	Youm YH	The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.	Nature medicine	2015	70
26553871	114548	Schmid-Burgk JL	A Genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Screen Identifies NEK7 as an Essential Component of NLRP3 Inflammasome Activation.	The Journal of biological chemistry	2016	25
26972847	114548	Iannitti RG	IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis.	Nature communications	2016	11
24411485	151306	Duboc H	The bile acid TGR5 membrane receptor: from basic research to clinical application.	Digestive and liver disease 	2014	28
24468803	151306	Joyce SA	The gut microbiota and the metabolic health of the host.	Current opinion in gastroenterology	2014	28
24821328	151306	Kuipers F	Beyond intestinal soap--bile acids in metabolic control.	Nature reviews. Endocrinology	2014	42
25584736	151306	Li T	Bile acids as metabolic regulators.	Current opinion in gastroenterology	2015	21
15331542	169026	Chimienti F	Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules.	Diabetes	2004	100
17942684	169026	Wenzlau JM	The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.	Proceedings of the National Academy of Sciences of the United States of America	2007	224
18264689	169026	Kirchhoff K	Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion.	Diabetologia	2008	82
18591387	169026	Wenzlau JM	A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes.	Diabetes	2008	52
19450229	169026	Pound LD	Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretion.	The Biochemical journal	2009	52
20858685	169026	Stene LC	Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY).	Diabetes	2010	57
21067382	169026	Knip M	Dietary intervention in infancy and later signs of beta-cell autoimmunity.	The New England journal of medicine	2010	57
22289814	169026	Ziegler AG	Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes.	Diabetologia	2012	39
24051378	169026	Tamaki M	The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance.	The Journal of clinical investigation	2013	39
24584071	169026	Flannick J	Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.	Nature genetics	2014	99
25015099	169026	Zhou Y	TCF7L2 is a master regulator of insulin production and processing.	Human molecular genetics	2014	28
25287711	169026	Rutter GA	SLC30A8 mutations in type 2 diabetes.	Diabetologia	2015	17
23018146	252995	Huh JY	FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise.	Metabolism	2012	127
23369227	252995	Choi YK	Serum irisin levels in new-onset type 2 diabetes.	Diabetes research and clinical practice	2013	56
23436919	252995	Moreno-Navarrete JM	Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance.	The Journal of clinical endocrinology and metabolism	2013	88
23619195	252995	Liu JJ	Lower circulating irisin is associated with type 2 diabetes mellitus.	Journal of diabetes and its complications	2013	59
24040023	252995	Raschke S	Evidence against a beneficial effect of irisin in humans.	PloS one	2013	52
24140091	252995	Polyzos SA	Irisin in patients with nonalcoholic fatty liver disease.	Metabolism	2014	26
24297848	252995	Kurdiova T	Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies.	The Journal of physiology	2014	40
24506871	252995	Lee P	Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans.	Cell metabolism	2014	109
24709991	252995	Yan B	Association of serum irisin with metabolic syndrome in obese Chinese adults.	PloS one	2014	22
25514098	252995	Huh JY	Irisin in response to exercise in humans with and without metabolic syndrome.	The Journal of clinical endocrinology and metabolism	2015	18
28211512	252995	Perakakis N	Physiology and role of irisin in glucose homeostasis.	Nature reviews. Endocrinology	2017	7
23884353	255738	Desai NR	AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.	Circulation	2013	32
25037695	255738	Roth EM	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.	International journal of cardiology	2014	38
25282519	255738	Raal FJ	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.	Lancet	2015	66
25778403	255738	Romagnuolo R	Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.	The Journal of biological chemistry	2015	27
26030325	255738	Bays H	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.	The Journal of clinical endocrinology and metabolism	2015	24
26578202	255738	Lipinski MJ	The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.	European heart journal	2016	18
26718096	255738	Banach M	Lipids, blood pressure and kidney update 2015.	Lipids in health and disease	2015	16
27701660	255738	Lotta LA	Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.	JAMA	2016	17
27959767	255738	Ference BA	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.	The New England journal of medicine	2016	15
